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Synthesis of 2-alkenyl and 2-arylbenzimidazoles, having a variety of functional groups, 
has been accomplished via a novel palladium-catalyzed reductive N-heteroannulation of 
2-nitro-N-alkyl or N-benzyl benzenamines.  The cyclization precursors are readily 
prepared from commercially available compounds by a variety of methods.  In addition, 
the first total synthesis of ht-13-A has been studied.  The key steps of the synthesis are a 
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Chapter 1 Introduction 
A. Benzimidazoles and 2-Substituted Benzimidazoles 
 The benzimidazole core may have been reported in the literature as early as 
18721, but was clearly identified by 18992 and the interest from synthetic chemists 
continues today3.  The general structures of benzimidazoles consist of a benzene ring 
fused to the 4 and 5 positions of an imidazole ring.  The numbering of benzimidazole 
starts with the protonated nitrogen of the imidazole ring and progresses towards the other 
nitrogen.  Some confusion could occur since the proton can shift between the two 
nitrogen atoms and consequently changes the numbering of the compound (Scheme 1).  
The benzimidazole with the lowest numbered substituents will be used in this document 
except in cases describing the work of others that use an alternate numbering system.  If 
the imidazole nitrogen is substituted then the numbering will always start with that 






















Scheme 1  Numbering of Benzimidazoles
5-methylbenzimidazole 6-methylbenzimidazole  
 
 The benzimidazole core is of interest to synthetic chemists because of its wide 
range of biological activities and its framework forming the base of some current 
pharmaceuticals.  For example, compounds containing a benzimidazole core have shown 
biological activity such as anti-infective, anticancer, antibacterial, antifungal, 
2 
 
anthelmintic, antiretroviral, antiallergic, and antitumor3a, 4, 5.  Possibly the most well 
known pharmaceuticals containing the benzimidazole core are the proton pump inhibitors 


























Prevacid (lansoprazole) Prilosec (omeprazole)
Nexium (esomeprazole)  
 
substituent in the 2-position are used in the treatment of peptic ulcers (proton pump 
inhibitors), compounds with a small substituent in the 2-position are usually 
anthelmintics (anti-worm).  Benzimidazole anthelmentics are used in both veterinary 
medicines to treat a wide range of animals6 and in human medicine.  Examples of current 
anthelmentics drugs include fenbendazole for animals6 and mebendazole for humans7.  
Other drugs with a 2-substituted benzimidazole core in use today include antihistaminics8 
such as mizolastine, anticoagulant Dabigatran9, and potential drugs such as the antitumor 
class of compounds pyrrolo[1,2-a]benzimidazoles10 (PBI) as seen in Figure 2.  
 In addition to pharmaceuticals and veterinary medicines, the benzimidazole core 
can be found in commercially available fungicides.  Examples of these types of 



















































Thiabendazole as well as the acaricide (pesticide targeting mites) Fenzaflor11.  
Unfortunately, fungicide resistance has become a problem for the most commonly used 
benzimidazole fungicides12. 
 The benzimidazole core can be seen in a wide variety of synthetic compounds, but 
there are very few examples of benzimidazoles in nature.  One of the few compounds 
isolated from a natural source, Kealiiquinone13 is a benzimidazole alkaloid isolated from 

















Fuberidazole Thiabendazole Fenzaflor  
 
nature is an axial ligand14 to cobalt found in Vitamin B12.  The ligand is named N-
























































B. 2-Vinyl and 2-Phenylbenzimidazoles 
 While 2-vinylbenzimidazoles can be found in the literature as early as 195215, 
there are very few articles published since that time.  Some possible reasons for this could 
be that 2-vinylbenzimidazoles have a tendency to polymerize16 and were prepared in low 
isolated yields17.  The tendency to polymerize was exploited with homopolymerization18 
as well as 2-vinylbenzimidazole copolymerized with a wide variety of compounds15. 
 Despite these limitations, the recent literature has shown a number of substituted 
2-vinylbenzimidazoles with promising biological activities.  Some examples of these 
styryl derivatives include fluorescent chemosensors for heparin detection19, possible 
HIV-1 (human immunodeficiency virus) integrase binding inhibitors20, possible 
inhibitors of monoamine oxidase B21, GTP-selective fluorescent chemosensors22, and 
fluorescent disperse dyes23 (Figure 5). 
 In contrast to the 2-vinylbenzimidazoles, numerous articles have been published 
on 2-phenylbenzimidazole and substituted 2-phenylbenzimidazoles.  Probably the most 
recognized commercial use of a substituted 2-phenylbenzimidazole is in sunscreens24.  
The purpose of the benzimidazoles in sunscreens is to act as UV filters with 2-
phenylbenzimidazole-4,6-disulfonic acid25 and 2-phenyl-5-sulfonic acid26 being two 
examples.  However, with newer methods of detection26, 27, questions about the safety of 
these compounds have been introduced.  Minimal reports of adverse reactions to 
phenylbenzimidazole sulfonic acid can be seen in the literature such as photocontact 
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one case of allergic reaction and considered it an exception30.  Other reports links 2-
phenylbenzimidazole and 2-phenylbenzimidazole-5-sulfonic acid to photosensitization of 
Guanine-specific DNA damage31 as well as DNA damage in the HaCaT keratinocytes 
with light irradiation, but no damage without light32.  The use of substituted 2-
phenylbenzimidazoles in cosmetics33 is also widespread.  The function of 2-
7 
 
phenylbenzimidazole-5-sulfonic acid in cosmetics is the same as in sunscreens, namely 
that of a UV filter34. 
Substituted 2-phenylbenzimidazoles have been tested for a wide range of 
biological activities.  A small sampling of the published results of substituted 2-
phenylbenzimidazoles for biological activity includes antibacterial activity against 
methicillin resistant Staphylococcus aureus35, AMP-activated protein kinase activators to 
fight obesity36, as topoisomerase I poisons37, disrupting of Golgi processing and potent 
activity against IgE38, as a novel peptide coupling reagent39, for antitumor activity40, for 
antimicrobial and antifungal activity41, for antioxidant properties42, and as inhibitors of 
HIV-1 reverse transcriptase43.  A few of the other possible uses of substituted 2-
phenylbenzimidazoles include their use in the indirect fluorescent determination of 
pharmaceutical compounds44, as accelerators for curing of epoxy resin45, in a complex 
with iridium to form an organic light emitting diode46, as an additive in electrolytic 
solution to effect dye-sensitized solar cell performance47, and as intermediates in organic 
reactions forming triazines48, diketones49, or benzotriazoles50.  A variety of the above 


































Organic Light Emitting Diode  
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C. Formation of 2-Substituted Benzimidazoles 
While there are numerous ways to prepare 2-substituted benzimidazoles51, two 
procedures are the most widely used.  The first is the Philips synthesis involving a 
condensation of 1,2-diaminobenzenes with a carboxylic acid or acid derivatives in the 
presence of an acid52 (Scheme 2, path A) and the other method involves the oxidative 
condensation of 1,2-diamines with aromatic aldehydes (Scheme 2, path B)53.  Advances 
in both pathways of the synthesis of 2-substituted benzimidazoles can be seen in the 
recent literature. 































 There have been many reports of updated syntheses since the original Phillips 
work condensing 1,2-diaminobenzenes with carboxylic acids.  Some of the most recent 
examples include the use of microwave heating54, a resin to avoid strong acids with 
microwave heating55, the alternative condensing agent N,N-
dimethylchlorosulfitemethaniminium chloride56, cyclocondensation with catalytic 
BF3·Et2O57, an enzymatic catalyst58, and the two step reactions between 1,2-
diaminobenzene and one equivalent of an acid chloride before employing BF3·Et2O as a 
10 
 
selective reagent for cyclodehydration59 or two equivalents of an acid chloride then 
cyclized using p-toluenesulfonic acid60 (Scheme 3). 
Scheme 3  2-Substituted Benzimidazoles from 1,2-Aminobenzenes and Acid Chlorides
NH2
NH2Cl
1) 2 eq CH3COCl
2) BF3·Et2O
85% (2 steps)

























 While the use of carboxylic acids with 1,2-diaminobenzenes was discussed in a 
wide range of articles from earlier years, the use of aldehydes with 1,2-diaminobenzenes 
seems to be the current method of choice when forming 2-substituted benzimidazoles.  A 
few of the results from the large number of papers published recently include the reaction 
of o-phenylenediamine derivatives and aldehydes in the presence of the organic salt 
ammonium acetate61, with air oxidation after condensation62, using 
(bromodimethyl)sulfonium bromide for oxidative dehydrogenation after condensation63, 
oxidation by hypervalent iodine64, and catalyzed by p-toluenesulfonic acid65, 
iron(III)/iron(II) redox cycle66, or Oxone®67.  In general, the recent references listed 
above use aromatic aldehydes to form substituted 2-phenylbenzimidazoles (Scheme 4). 
11 
 
































 Other recent improvements include the development of environmentally friendly 
reactions to 2-substituted benzimidazoles.  Examples include the use of iodine as a green 
oxidant68, oxidation with activated carbon and molecular oxygen69, the oxidative 
condensation promoted by KHSO470, use of zeolites71, and the use of sulfamic acid as an 
eco-friendly catalyst72.  There are also a few methods that do not use 1,2-
diaminobenzenes when forming 2-substituted benzimidazoles.  These include the use of 
N-arylamidines with hypochlorite and base73 and the tosylation of N-arylamidoximes in 
the presence of triethylamine74 (Scheme 5). 
12 
 




















There have also been a few metal-catalyzed syntheses to form 2-substituted 
benzimidazoles.  A few examples include the reactions of amidines with lead tetraacetate 
oxidation75, a palladium-catalyzed reaction76, or an iron-catalyzed oxidation77 (Scheme  






























6).  In addition, an annulation to form 2-vinylbenzimidazole using a ruthenium-catalyst 
has been reported78.  It is interesting to note that with acetonitrile as the solvent only the 
benzimidazole was formed, but in cyclooctene both a higher yield of the benzimidazole 
and the side product 2-methylquinoxaline were observed (Scheme 7).  An alternate 
published procedure to 2-vinylbenzimidazoles uses an anion-exchange resin with 
substituted pyridinium salts79. 















D. Developed Method 
 With the number of diverse uses for 2-substituted benzimidazoles, a mild and 
efficient synthetic method would be useful.  The previously discussed reactions all suffer 
from one or more problems such as a lack of diversity in the starting materials, strongly 
acidic or harsh dehydrating conditions, high temperatures, prolonged reaction times, toxic 
solvents, use of a large amount of oxidant, tedious work-ups, poor yields, or side 
products.  Thus, based on a relatively mild palladium-catalyzed N-heteroannulations to 
give indoles recently developed in our laboratories80, we attempted to use similar reaction 
conditions for the formation of benzimidazoles.  In addition to indoles, the developed 
reaction has been used to form quinoxalines and quinoxalinones81, carbazoles82, 
carbazolones83, and β-carbolines84.  The N-heteroannulation for each system consists of a 
palladium source, ligand, and carbon monoxide, but the reaction conditions are slightly 
different in each system to improve yields and the conditions have yet to be fully 
optimized.  
In our original experiment, N-2-(propen-1-yl)benzenamine was prepared by 
nucleophilic aromatic substitution of methyl 2-bromo-3-nitrobenzoate (3) with 1-amino-
2-propene.  Reductive N-heteroannulation of the benzenamine 5 gave the substituted 2-
vinylbenzimidazole (27) in 34% yield (Scheme 8). Encouraged by the results from the 
initial reaction sequence, the scope and limitations of the palladium-catalyzed formation 


















Pd(dba)2, dppp, CO (6 atm)





E. Natural Product Syntheses of ht-13-A and ht-13-B 
 In a recent patent85, a number of compounds were isolated from Streptomyces sp. 
PA-48561 that have an affinity for serotonin receptors.  The patent claims that the 
compounds are useful as remedies for central nervous system diseases such as anxiety 
neuroses, depression, schizophrenia, cerebral apoplexy, dementia, pain, and Parkinson’s 
disease.  Of the compounds isolated, two were of synthetic interest for the utilization of 
the reductive N-heteroannulation developed in our laboratories.  The structure of ht-13-A 
and ht-13-B (Figure 7) has a similar motif to compounds we previously synthesized80, 
such as the indole core and a ring fused to the three and four positions of the indole.  The 
envisioned synthetic route would be similar to the methodology developed using a Heck 
reaction followed by a reductive N-heteroannulation to form the indole ring.  The Heck 
precursor would be formed from a Mitsunobu reaction which would set the 
stereochemistry of the molecule.  To date, no synthesis of either ht-13-A or ht-13-B has 













ht-13-A 1 ht-13-B 2  
 
 To apply the developed 3,4-fused indole methodology to a natural product 
synthesis a number of possible targets having this core were considered.  The fused ring 
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of the possible targets include those with a heteroatom, usually oxygen or nitrogen, as 
well as rings that are all carbon based.  Possible compounds included pibocin A86, an 
ergoline marine alkaloid, hyrtiazepine87, an azepino-indole-type alkaloid, clavicipitic 
acid88, an intermediate in ergot alkaloid formation, or novel indoloazepine derivatives89 
which could be used as vasopressin V2 receptor antagonists (Figure 8).  ht-13-A and ht-
13-B were chosen as the targets for the natural product over the other possibilities for a 
number of reasons.  While all of the possible targets include a fused ring and an indole 
core the other substituents were a factor in choosing a target.  The pyrrolidine ring on ht-
13-A and ht-13-B could be made following literature procedures while the other targets 
had no clear path to the substituents.  Also, the retrosynthetic sequence for ht-13-A and 
ht-13-B was hoped to be only three key steps from known starting materials while all the 
other targets looked to include many more synthetic steps.  In the developed 
methodology, the Heck reaction forming a seven member fused ring, as well as the indole 
cyclization, gave the best results so a target with a seven membered ring was favored.  
Finally, since no other routes are known to either ht-13-A or ht-13-B a synthesis would 




































Indoloazepine derivative  
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Chapter 2 Results and Discussion 
A. Preparation of N-Allyl and N-Benzyl-2-Nitrobenzenamines 
 Our general route to 2-vinyl or 2-phenyl substituted benzimidazoles includes the 
synthesis of N-allyl or N-benzyl-2-nitrobenzenamines followed by the recently developed 
N-heterocyclization.  In order to examine the palladium-catalyzed N-heteroannulation to 
give benzimidazoles, a variety of N-allyl or N-benzyl-2-nitrobenzenamines were 
synthesized.  The compounds were selected to introduce a variety of substituents such as 
a halide (chloride), electron withdrawing groups (ester and nitro), and an electron 
donating group (methoxy) on the benzimidazole.  Further diversity was accomplished by 
the selection of compounds such as those that include the use of a pyridine ring in the 
place of the benzene ring, compounds that can be used to form isomers, and compounds 
where more than one position could participate in the N-heteroannulation. 
The original method utilized to form N-allyl or N-benzyl-2-nitrobenzenamines 
was nucleophilic aromatic substitution90 using 2-halo-1-nitroarenes and amines.  The 
three substrates synthesized in this manner were methyl 3-nitro-2-(N-(2-propen-1-
yl))aminobenzoate (5), N-(2-propen-1-yl) 2-(N-(2-propen-1-yl))amino-3-nitrobenzamide 
(6), and methyl 2-(N-benzylamino)-3-nitrobenzoate (7) as seen in Table 1.  Compound 5 
was formed by stirring methyl 2-bromo-1-nitrobenzoate (3) with allylamine and sulfuric 
acid.  Stirring of 3 with benzylamine yielded compound 7 without the need of the sulfuric 
acid catalyst.   The nitrobenzamide 6 was produced from the double addition of 
allylamine to 2-bromo-3-nitrobenzoic acid (4) when they were reacted in the presence of 
oxalyl chloride.  While these methods worked well for a few compounds it did not give 
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satisfactory yields for all the substrates examined and not all starting materials were 
readily available. 



























Table 1 Nucleophilic Aromatic Substitution Forming 2-Nitrobenzenaminesa













 An alternate procedure to nucleophilic aromatic substitution was needed and a 
search of the literature led to the reductive amination91 of 2-nitrobenzenamines with 
aldehydes.  Three more substrates were synthesized in this manner, specifically N-
benzyl-2-nitrobenzenamine 8, N-4-nitrobenzyl-2-nitrobenzenamine 9, and N-benzyl-5-
chloro-2-nitrobenzenamine 10 (Table 2).  Compounds 8 and 10 were synthesized using 
the appropriate amine, benzaldehyde, and acetic acid stirring at room temperature then 
reduced with sodium triacetoxyborohydride.  However, the synthesis of compound 9 did 
not require acid, but instead a Dean-Stark trap was utilized to remove water forming the 
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condensation product which was subsequently reduced by sodium triacetoxyborohydride.  
Unfortunately, after a good yield in forming 8, the yields for the other two compounds 
fell dramatically driving the need for another method that would give higher yields. 
Table 2 Reductive Amination Forming N-Benzyl-2-nitrobenzenaminesa



































  After the nucleophilic aromatic substitution and reductive amination methods did 
not provide satisfactory results, the annulation precursors were prepared using a 
Buckwald-Hartwig-type palladium-catalyzed amination of 2-halo-1-nitroarenes92.  This 
method of preparation gave the best yields for the majority of precursors and the results 
can be seen in Table 3.  Typical reaction conditions consist of heating the proper 2-halo-
1-nitroarenes and amines with palladium diacetate, racemic 2,2′-bis(diphenylphosphino)-
1,1′-binaphthyl (binap), and cesium carbonate to form the corresponding N-allyl or N- 
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Entry Nitrobenzene Amine Product Yield
 
benzyl-2-nitrobenzenamine.  Exact reaction conditions and amounts of material used for 
all reactions can be found in the experimental section. 
 In addition to the methods listed above, a number of compounds were synthesized 
by following published routes.  The four compounds produced in this way are N-
cinnamyl-2-nitrobenzenamine (21), 2-nitro-N-phenethylbenzenamine (22), N-benzyl-4-
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chloro-2-nitrobenzenamine (23), and N-benzyl-3-nitropyridin-2-amine (24) which are 















23 24  
 
 Finally, to test the capability of the N-heteroannulation using an amide instead of 
an amine, compound 25 was synthesized according to a literature procedure93.  N-Benzyl-
2-nitrobenzenamine (8) was reacted with acetyl chloride with catalytic sulfuric acid in 
acetic anhydride to give amide 25 with a yield of 91% (Scheme 9).   













B. Formation of 2-Substituted Benzimidazoles 
 With a variety of N-benzyl and N-allyl-2-nitroarenes available, N-benzyl-2-
nitrobenzenamine (8) was used as a model system for the initial screening of the reaction 
conditions for the N-heteroannulation.  This compound was chosen because the product, 
2-phenylbenzimidazole (30), is substantially more stable when compared with the 2-
ethenylbenzimidazoles such as 26.  As discussed in the introduction, the 2-
vinylbenzimidazoles are very prone to polymerization.  The screening reactions were 
performed at 120 ºC for 20-24 hours in all cases, and the amount of product was 
determined after purification by column chromatography.  Starting material (8) was 
obtained in varying amounts, but since it co-elutes with bis(dibenzylidene)acetone (dba) 
the amount was not quantified. 
 The initial screen of the reaction conditions included examining the palladium 
catalyst, ligands, solvent, pressure, and pressurizing gas (Table 4).  While the study is by 
no means exhaustive it did lead to reaction conditions that gave quality yields in most 
cases.   In the initial reaction attempted (Scheme 8) both bis(1,3-
diphenylphosphino)propane (dppp) and 1,10-phenanthroline (phen) were used as ligands.  
This combination has previously been employed successfully in the synthesis 3,4-fused 
indoles80, 1,2-dihydro-4(3H)-carbazolones83, and β-carbolines84.  However, for the 
transformation of 8 to 30, a much higher yield was achieved using only 1,10-
phenanthroline as the ligand (Table 4, entry 2).  Palladium diacetate (Pd(OAc)2) was 
examined as a catalyst in place of bis(dibenzylidene)acetone palladium (Pd(dba)2), but 
did not perform as well as the original catalyst (entry 3).  The absence of any palladium 
catalyst resulted in a 96% recovery of starting material (entry 4). 
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Entry Catalyst Ligands Solvent Yield of 30 (%)




















































































a The temperature for all reactions was 120 ºC
b Compound 8 was recovered in 96%
c 2-Nitrobenzenamine was also isolated in 22%




 Dimethyl formamide (DMF) was used in the original sequence, but a variety of 
other solvents were explored.  Acetonitrile (MeCN), N-methylpyrrolidinone (NMP), and 
toluene were all tested under the same reaction conditions (entries 5, 6, 7).  Nonetheless, 
DMF was shown to be the best of the solvents tested for the reaction conditions.  
Previous work94 has shown DMF to be the optimal solvent for the cyclization of 2-nitro-
1-alkenylarenes to give indoles. 
 Carbon monoxide is integral to the reaction as replacing it with an argon 
atmosphere (entry 14) resulted in no reaction.  A carbon monoxide pressure of 6 atm. was 
found to be optimal for this reaction as lowering or raising the pressure only resulted in 
27 
 
diminishing yields (entries 8-13).  In contrast to the Ru3(CO)12 catalyst discussed in the 
introduction (Scheme 7), no quinoxaline was observed under any reaction conditions for 
any of the substrates examined including using cyclooctene as the solvent.  Reaction of 8 
in cyclooctene resulted in quantitative recovery of the starting material. 
 After discovering the best conditions and with an array of substrates available, the 
scope and limitations of the annulation reactions were examined.  All N-substituted-2-
nitroarenes were subjected to the developed reaction conditions for relatively long 
reaction times (2-8 days) until completion as monitored by TLC.  The results of the N-
heteroannulation can be seen in Table 5. 
 All four N-allylated-2-nitrobenzenamines examined underwent annulations to 
give 2-alkenyl-substituted benzimidazoles (entries 1-4).  Likewise, the vast majority of 
N-benzyl-2-nitrobenzenamines reacted to form the corresponding substituted 
benzimidazole (entries 5-15 and 17-21).  Functional groups were mostly tolerated on both 
the benzyl ring (entries 6 and 7) and the 2-nitrobenzenamine ring (entries 8-14 and 17-
18).  However, having a nitro-group on either ring resulted in no recovered starting 
material and no identifiable products formed (entries 7 and 9).  This lack of formed 
product and loss of starting material was also seen from the reaction of the pyridine 
derivative 24 (entry 15).  This is not entirely surprising as previous studies have shown 
that groups containing nitrogen can poison palladium catalysts95.  In addition to these 
examples, reaction of N-substituted-2-nitroarenes leading to fused systems worked well 
in some cases (entries 19-20), but not as well in others (entries 17-18).  Unfortunately, the 












































































































































































































a See Chapter 3 for experimental details
b Prepared according to literature procedure
c No benzimidazole, starting material, or any other identified products were observed
d In addition, 28% of 15 was also isolated














Entry N-Substituted-2-nitroarene Benzimidazole Yield
 
 
 It is evident, from examples in Table 5, that in order for a methylene group to 
participate in the cyclization it must be activated by an adjacent aryl or alkenyl group.  To 
begin with, having a two carbon chain, such as in N-(2-phenyl-1-ethyl)-2-
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nitrobenzenamine, did not lead to the benzimidazole being formed under the reaction 
conditions, but did produce minute quantities of a number of unidentified products (entry 
16).  In addition, no reaction of the N-substituted methyl groups of either 14 or 15 was 
observed while the expected benzimidazoles were formed (entries 10 and 11).  Finally, 
when two different methylenes were present in the same molecule (19), only the benzylic 
methylene reacted to form the benzimidazole nucleus (entry 19). 
 The mechanism of the N-heteroannulation to form benzimidazoles is presently 
unclear.  However, a palladium bound nitrene could be the possible reactive species 
based on similar suggested mechanisms (Scheme 10).  For example, a metal-bound  




























nitrene followed by carbon-hydrogen bond insertion was suggested for the ruthenium-
catalyzed reaction seen in Scheme 7.  Also, ruthenium96 and palladium97 in the presence 
of carbon monoxide have been shown to catalyze the formation of nitrogen containing 
heterocycles.  In addition, selenium98 and ruthenium99 with carbon monoxide has also 
been shown to catalyze the formation of 2-arylbenzimidazoles from 2-nitro-N-
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(phenylmethylene)benzenamine, the imine derived from the reaction of 2-
nitrobenzenamine and benzaldehyde. 
Given the literature precedence, an oxidation of the amine to an imine followed 
by cyclization was initially considered as a possible reaction path.  However, reaction of 
preformed 2-nitro-N-(phenylmethylene)benzenamine under the developed reaction 
conditions did not produce the corresponding 2-phenylbenzimidazole (30), but only 
resulted in hydrolysis of the imine back to the original starting materials (Scheme 11). 







30 8  
 
 Another mechanistic possibility is a base mediated cyclization to form a N-
hydroxybenzimidazole followed by a palladium-catalyzed deoxygenation.  This does not 
appear to be the case since no reaction is observed in the absence of palladium (Table 4, 
entry 4) and the starting material is recovered unchanged even after prolonged reaction 
times.  Quenching the reaction before complete consumption of starting material only 




C. Methodology of 2-Vinyl and 2-Phenylbenzimidazoles Conclusion 
 The developed methodology to substituted benzimidazoles was shown to be not 
only a viable route, but also a successful one.  The method is a relative mild and 
expedient palladium-catalyzed synthesis of 2-alkenyl or 2-aryl-substituted 
benzimidazoles starting from readily available N-allyl or N-benzyl-2-nitrobenzenamines.  
The reaction involves, at least formally, an unusual insertion into a sp3-hybridized 
carbon-hydrogen bond.  The reaction sequence is flexible and a variety of functional 
groups are tolerated.  Although numerous methods for the preparation of benzimidazoles 
exist, the presented reaction may offer an advantage when acid sensitive or oxidation 
prone functional groups are present in the target molecule. 
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D. Preparation of Starting Materials for Natural Product Synthesis 
 Retrosynthetically, the final key step in the synthesis of natural products ht-13-A 
and ht-13-B (Scheme 12) will be the developed palladium-catalyzed N-heteroannulation 
to form the indole ring.  The precursor to this reaction would come from a Heck-type 
reaction and the precursor for the Heck reaction will be formed by a Mitsunobu reaction 
between phenol 47 (X=Br) or 48 (X=I) and the proper alcohol (Scheme 12).  The 
proposed route requires a variety of starting materials to be synthesized, including 2-
bromo or 2-iodo-3-nitrophenol and the proper pyrrolidine ring. 

































X =Br or I  
 
 Literature procedures were followed to form the needed pyrrolidine rings as well 
as the 2-halo-3-nitrophenol starting materials.  Following literature procedures, 2-amino-
3-nitrophenol was transformed into 2-bromo-3-nitrophenol100 (47) or 2-iodo-3-
nitrophenol101 (48) using a Sandmeyer-type reaction (Scheme 13).  Both compounds were 
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synthesized with the idea of obtaining the best possible yield in the Heck reaction later in 
the synthetic sequence. 










1) HBr, H2O, dioxanes
2) NaNO2, H2O, 0 ºC
3) CuBr, H2O, HBr
      32% (3 steps)
1) NaNO2, H2SO4, H2O, DMSO, 0 ºC
2) KI, 51% (2 steps)a
47
48
aPrepared by colleague Christopher Dacko  
  
 A small number of different routes were attempted for the synthesis of the 
pyrrolidine ring.  Reasons for the different approaches include the failure of the ring to 
react under Mitsunobu reaction, failure to react to form the correct ring, and lack of 
literature precedence to form the correct stereoisomer.  The original method used for the 
construction of the pyrrolidine ring was following a literature procedure102, although 
forming the enantiomer of the publisher sequence (Scheme 14).  The synthesis starts from 
commercially available (R)-malic acid reacting with acetyl chloride and methylamine to 
form the imide 49.  Anhydrous hydrogen chloride gas was used to remove the acetyl 
group followed by protection of the resulting alcohol using t-butyl dimethyl silyl chloride 
(TBSCl).  The regiospecific reduction of one carbonyl group was achieved by sodium 
borohydride.  A mixture of isomers was formed in this reaction, but the mixture of 
isomers does not affect later reactions to set the stereochemistry at that position.  
Employing a Williamson ether synthesis using sodium hydride to deprotonate followed  
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by methyl iodide, the alcohols (52) were converted to the methyl ethers (53).  Treatment 
of 53 with allyl trimethylsilane in the presence of titanium tetrachloride gave compounds 
54 and 55.  The major cis-isomer (55) is the desired pyrrolidine ring that would lead to 
the proper stereochemistry in ht-13-A and ht-13-B.  Deprotection of the TBS ether of 
each separate isomer was achieved by the use of tetrabutyl ammonium fluoride (TBAF) 
and gave the needed pyrrolidine ring for the Mitsunobu reaction.  Finally, the alcohol of 
the cis-isomer 57 was transformed to a better leaving group in expectation of a SN2-type 
reaction.  It was envisioned that the pyrrolidinone 57 would lead to both ht-13-A and ht-
13-B with either a reduction of the remaining carbonyl group (ht-13-A) or using Tebbe or 
Petasis reagents to transform the carbonyl group to an alkene followed by a stereospecific 
reduction to a methyl group with the proper stereochemistry (ht-13-B). 
 Unfortunately, pyrrolidinone 57 failed to form the desired product in the 
Mitsunobu reaction (as seen in Chapter 2, Section E) and thus another strategy was 
needed.  Following another literature procedure103, compound 62 was formed to react 
with 2-halo-3-nitrophenol under the Mitsunobu reaction conditions (Scheme 15). 






























Starting from commercially available D-(+)-malic acid diethyl ester, the alcohol was 
protected using dihydropyran and pyridinium p-toluenesulfonate (PPTS).  After 
protection of the alcohol, the two ester groups were reduced to the diol 60 using lithium 
aluminum hydride (LAH).  The alcohol groups in 60 were reacted with methane 
sulfonylchloride (MsCl) in the presence of a base forming 61 which was then reacted 
with methane sulfonic acid (MsOH) to remove the tetrahydropyran (THP) protecting 
group.  It was hoped that compound 62 would successfully undergo the Mitsunobu 
reaction then cyclize to the pyrrolidine ring and lead to both ht-13-A and ht-13-B.  
Although that reaction worked, later steps in the sequence failed (see Chapter 2, section 
E). 
 After two unsuccessful ventures, a route that led to positive results was found.  
Instead of trying to form one starting material leading to both ht-13-A and ht-13-B, it was 
decided that separate pyrrolidine rings were needed for each compound.  The target ring 
that would lead to ht-13-A was partially made in the original synthesis (Scheme 16).  
Compound 57 was reduced using LAH, but was found to not be stable upon storing.  
Thus, once formed it was reacted under the Mitsunobu reaction conditions as quickly as 
possible. 



















 The route to the pyrrolidine ring that would lead to ht-13-B is a collection of 
literature procedures leading to ring 73 (Scheme 17).  The synthesis starts with the 
transformation of trans-4-hydroxy-L-proline to the methyl ester 64 using thionyl chloride 
in methanol104.  The amine is then protected using di-tert-butyl dicarbonate anhydride 
(Boc2O) followed by protection of the alcohol with a TBS group giving compound 66105.  
After the two protections, the methyl ester was reduced using sodium borohydride and 
lithium chloride to yield the alcohol 67106.  The formed alcohol was then converted to the 
methanesulfonyl ether 68 and reduced to the pyrrolidine 69 using lithium 
triethylborohydride105.  Oxidation of the methylene in 69 to a carbonyl was accomplished 
using ruthenium oxide and sodium periodate to yield the amide 70107.  The amide 
carbonyl was reduced, using lithium triethylborohydride, to an alcohol that was 
transformed to the methyl ether by PPTS and methanol giving compound 71107.  The allyl 
group was then introduced as previously shown using allyl trimethylsilane and titianium 
tetrachloride, but the Boc protecting group was unexpectedly removed.  The deprotected 
mixture of isomers (72) was reprotected using Boc2O to give the desired allylation 
products (73).  Finally, the mixture of isomers was subjected to TBAF to remove the TBS 
protecting group and separated108 to give compounds 74 and 75. 
 In addition to the loss of a Boc group, the loss of another protecting group was 
experienced (Scheme 18).  In one attempted sequence to get to pyrrolidine 63 that was 
later abandoned, the TBS protecting group was inadvertently removed in two separate 
steps.  During the allylation reaction of pyrrolidinone 53 the loss of the TBS group was 
observed as a mixture of isomers in addition to obtaining the desired products 54 and 55.  
The free alcohols were reprotected and separated to give the desired TBS ethers. 
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Reduction of the cis-isomer again leads to unintended removal of the TBS protecting 
group in addition to the desired pyrrolidine 63.  As the next step in the sequence is the 
removal of the TBS group, the crude mixture was subjected to the deprotection 
conditions giving the desired pyrrolidine 63. 






































E. Formation of Ether (Mitsunobu Reaction) 
 The Mitsunobu reaction was developed in its most recognized form by Professor 
Oyo Mitsunobu in 1967109.  The usual protocol involves the reaction of an alcohol and an 
acid/pronucleophile promoted by a phosphane and an azodicarboxylate or 
azodicarboxamide under mild conditions (Scheme 19).  Many acid/pronucleophiles have 
been used such as carboxylic acids, phenols, and imides to prepare esters, ethers, or 
carbon-nitrogen bonds.  The Mitsunobu reaction is popular due to its stereoselectivity, 
ability to tolerate a large range of functional groups, and the mild conditions.  The main 
drawback of the Mitsunobu is that the by-products phosphane oxide and 
hydrazinedicarboxylate or hydrazinedicarboxamide tend to co-elute with the desired 
product.  A wide range of uses of the Mitsunobu reaction has been published since the 
original manuscript110 and current studies towards improvements are ongoing111.  While 
the numerous uses of the Mitsunobu reaction are found in the synthesis of steroids, 
carbohydrates, or nucleosides, a relatively small number of papers report the use in 
preparation of alkaloidal compounds112. 











NR'' R''+ + +
 
 
 Using the originally synthesized cis-pyrrolidinone 57 and 2-bromo-3-nitrophenol 
(47), the Mitsunobu reaction was attempted.  Initially, diethylazodicarboxylate (DEAD) 
and triphenylphosphine were the reagents used in the reaction, but no product was formed 
(76).  Given that DEAD is no longer commercially available, the use of 
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diisopropylazodicarboxylate (DIAD) with triphenylphosphine was next attempted, but 
again no product was seen.  Lowering of the temperature to -20 ºC with DIAD and 
triphenylphosphine still yielded no product.  To be sure that steric hindrance was not the 
problem, the diasteriomer (56) of pyrrolidinone 57 was reacted under the DIAD and 
triphenylphosphine conditions, but once more no product was observed (77).  Finally, the  

















































mesylate 58 was reacted in a SN2 type reaction with cesium carbonate or sodium hydride 
as a base.  These reactions also did not lead to any of the desired ether (Scheme 20).  It is 
thought that the slightly basic conditions of the Mitsunobu reaction give the elimination 
product forming an alkene (78) as shown in Scheme 20.  This is not unlikely as a recent 
paper113 describes similar elimination products from β-thioalkoxy alcohols (Scheme 21). 














 Given that the pyrrolidinone ring failed to react under the Mitsunobu reaction 
conditions, mostly likely because of the acidic proton, an alternate method was needed.  
Compound 62 was constructed knowing that the protons would be much less acidic and 
thus it would be more likely to form the desired ether.  Subjecting the alcohol 62 to the 
Mitsunobu conditions with 2-bromo-3-nitrophenol (47), triphenylphosphine, and DIAD 
lead to the desired ether (79) in excellent yield.  To form the pyrrolidine ring and further 
the reaction sequence, literature procedures114 were followed to form 80 in two steps.  
The dimesylate 79 was transformed to the cyclic hydroxylamine which was then oxidized 
to the nitrone 80.  An allylation of the nitrone was attempted following two separate 
literature procedures.  The first attempted was made using allyl TMS and titanium 
tetrachloride102, but no product (81) was seen.  Likewise, no product (81) was formed 



































 Finally, after removal of the carbonyl group in pyrrolidinone 57 either by 
reduction (Scheme 16) or by changing routes (Scheme 17), the Mitsunobu reaction was 
accomplished successfully.  Using the conditions previously attempted, 2-halo-3-
nitrophenol, DIAD, and triphenylphosphine were reacted to give the desired ethers in 
good yields.  Both 2-bromo and 2-iodo-3-nitrophenol were used in the reaction so that the 
next step in the sequence, the Heck reaction, could be examined for the best possible 
results.  The pyrrolidine ring (63) that would lead to ht-13-A and the ring (74) that would 
lead to ht-13-B were both reacted under the Mitsunobu conditions and gave the 
corresponding ethers in good yields (Scheme 23). 
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84 (X=Br 41%, 76% BRSM)








F. Intramolecular Heck Reaction 
 The Heck reaction has become one of the most versatile methods for the 
preparation of carbon-carbon bonds since it was first introduced116.  The Heck reaction is 
the second key step in our general scheme to the natural products ht-13-A (1) and ht-13-B 
(2).  It is used to form the fused ring and to position the double bond for cyclization to the 
indole while not affecting the stereochemistry of the molecules (Scheme 24).  Our 
previous methodology80 to fused indoles demonstrated the feasibility of using the Heck 
reaction to form a seven member heterocyclic ring and leading into the N-






82 (X=Br, R=H, R'=CH3)
83 (X=I, R=H, R'=CH3)
84 (X=Br, R=CH3, R'=BOC)
85 (X=I, R=CH3, R'=BOC)











The initial attempt of the Heck reaction was utilizing the same conditions 
developed during the methodology, namely the substrate (85), palladium diacetate, and 
tri-o-tolylphosphine in triethylamine at 120 ºC.  However, these conditions only result in 
recovered starting material (Table 6, entry 1).  A recent paper117 provided alternate 
reaction conditions that gave promising results.  The reaction of the same substrate (85) 
with palladium diacetate, triphenylphosphine, and silver carbonate in DMF gave the 
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desired product in 31% yield (entry 2).  The same conditions using the bromo-substituted 
substrate (84) gave a similar 35% yield (entry 4).  Unfortunately, the same conditions 
with substrate 83 gave no product, starting material, or other isolatable products (entry 5).  
Reacting compound 84 under the original conditions (Pd(OAc)2, P(o-tolyl)3, NEt3) gave a 
similar yield to the other reactions (entry 3). 
Entry Substrate Conditions Yield
1
87, 35%







































G. Reductive N-Heteroannulation 
 Our previously published methodology80 gave yields from 33-83% for the 
reductive N-heteroannulation forming 3,4-fused indoles.  The cyclization conditions of 
this methodology consist of bis(dibenzylidenacetone)palladium, 1,10-phenanthroline, and 
1,3-bis(diphenylphosphino)propane in DMF under carbon monoxide at six atmospheres.  
Subjecting compound 87 to these conditions did not give the expected indole or any other 
identifiable products (Table 7).  Other heterocycles have been synthesized in our group 
using alternate conditions or palladium diacetate and 1,10-phenanthroline under a carbon 
monoxide atmosphere with good results.  Attempting these conditions gave promising 
results in the crude mixture, but with the small amounts used and the difficulty in the 
separation no product was able to be isolated. 
Entry Substrate Conditions Yield










120 ºC, 6 atm CO
Pd(OAc)2, phen,
DMF, 120 ºC,






H. Natural Products ht-13-A and ht-13-B Conclusions 
 The envisioned routes to ht-13-A and ht-13-B hold promise with the short, 
concise total synthesis.  However, the total syntheses have not been completed.  The key 
steps of a Mitsunobu reaction, Heck reaction, and indole cyclization utilizing a reductive 
N-heteroannulation have all shown potential, but optimization is still in progress.  Now 
that the Mitsunobu reaction and Heck reaction are effective a larger amount of precursor 
compounds for the N-heteroannulation should be possible and allow for reactions to be 
performed on a larger scale.  A larger scale should also help in finding the best method to 
purify the natural product ht-13-A and the N-Boc protected precursor to ht-13-B. 
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Chapter 3 Experimental 
A. General Procedures 
All NMR spectra were determined in CDCl3 at 600 MHz (1H NMR) and 150 MHz (13C 
NMR). The chemical shifts are expressed in δ values relative to Me4Si (0.00, 1H and 13C) 
or CDCl3 (77.00, 13C) internal standards. Tetrahydrofuran (THF) and diethyl ether were 
distilled from sodium benzophenone ketyl prior to use. Toluene, hexanes, and EtOAc 
were distilled from calcium hydride. Chemicals prepared according to literature 
procedures have been footnoted the first time used; all other reagents were obtained from 
commercial sources and used as received. All reactions were performed in oven-dried 
glassware under an argon atmosphere unless otherwise stated. Solvents were removed 
from crude reaction mixtures and products on a rotary evaporator at water aspirator 
pressure. Melting points were determined on a MelTemp and are uncorrected. Elemental 
analyses were performed in the Department of Chemical Engineering, College of 
Engineering and Mineral Resources, West Virginia University. 
 
B. Experimental 
Methyl 3-nitro-2-(N-(2-propen-1-yl))aminobenzoate (5) 
To a solution of methyl 2-bromo-3-nitrobenzoate (1.12 g, 4.31 mmol) in dichloromethane 
(50 mL) was added 2-propen-1-ylamine (350 mL, 4.66 mmol) and the reaction mixture 
was stirred at ambient temperature (23 h). Concentrated sulfuric acid (5 drops) was added 
and three portions of 2-propen-1-ylamine (330 mL, 4.40 mmol) were added 
(immediately, after 21.5 h, and after 24 h). The solution was heated at 50 °C for this 
entire period and for an additional 23 h after the last addition. The solvents were removed 
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on a rotary evaporator at water aspirator pressure and the residue was purified by 
chromatography (hexanes/EtOAc, 9:1) to give 5 (890 mg, 3.77, 87%) as a pale brown 
solid. Mp 60–61 °C; 1H NMR: δ 8.56 (br s, 1H), 8.08 (dd, J=7.2, 1.2 Hz, 1H), 7.97 (dd, 
J=7.8, 1.8 Hz, 1H), 6.69 (t, J=7.8 Hz, 1H), 5.85–5.91 (m, 1H), 5.32 (d, J=16.8 Hz, 1H), 
5.22 (d, J=10.2 Hz, 1H), 3.91 (s, 3H), 3.61 (s, 2H); 13C NMR: δ 167.7, 145.3, 137.4, 
136.9, 133.6, 131.5, 118.0, 116.8, 114.6, 52.4, 49.1; IR (neat): 1687, 1523, 1344, 
1121 cm−1; Anal. Calcd for C11H12N2O4: C, 55.93; H, 5.12. Found: C, 56.05; H, 5.58; 
HRMS calcd for C11H13N2O4 (M+H+): 237.0875, found: 237.0870. 
 
N-(2-Propen-1-yl) 2-(N-(2-propen-1-yl))amino-3-nitrobenzamide (6) 
To a solution of 2-bromo-3-nitrobenzoic acid (2.06 g, 8.37 mmol) in benzene (20 mL) at 
0 °C was added oxalyl chloride (4.0 mL, 45.9 mmol) via syringe. The resulting solution 
was stirred (0 °C, 10 min, ambient temperature, 1 h, and at reflux, 1 h), and the solvent 
and excess reagents were removed. The crude product was dissolved in benzene (20 mL), 
N-(2-propen-1-yl)amine (2.0 mL, 26.7 mmol) in benzene (10 mL) was added via pipette, 
and the resulting solution was stirred at ambient temperature (68 h). The solvent was 
removed on a rotary evaporator at water aspirator pressure and the crude product was 
purified by chromatography (hexanes/EtOAc, 6:4) to give 6 (1.05 g, 4.02 mmol, 48%) as 
a yellow solid followed by N-(2-propen-1-yl) 2-bromo-3-nitrobenzamide (740 mg, 2.60, 
31%) as a yellow solid. Data for 6: mp 59–60 °C; 1H NMR: δ 8.16 (dd, J=9.0, 1.2 Hz, 
1H), 7.76 (dd, J=7.8, 1.2 Hz, 1H), 7.64 (br s, 1H), 6.85 (t, J=7.8 Hz, 1H), 6.72 (br s, 1H), 
5.96–5.84 (m, 2H), 5.29–5.25 (m, 2H), 5.23–5.18 (m, 2H), 4.07 (t, J=6.0 Hz, 2H), 3.80 (t, 
J=6.0 Hz, 2H); 13C NMR: δ 167.2, 143.7, 137.8, 136.4, 133.8, 133.4, 128.7, 126.6, 117.6, 
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117.5, 117.5, 50.6, 42.5; IR (neat): 3311, 1637, 1488, 1270, 925 cm−1; Anal. Calcd for 
C13H15N3O3: C, 59.76; H, 5.79. Found: C, 59.43; H, 6.06. 
 
Methyl 2-(N-benzylamino)-3-nitrobenzoate (7)118  
A solution of methyl 2-bromo-3-nitrobenzoate (261 mg, 1.00 mmol) and benzylamine 
(230 µL, 2.11 mmol) in dichloromethane (10 mL) was stirred at ambient temperature 
(23 h). Additional benzylamine (12 µL, 1.10 mmol) was added and the solution was 
stirred at ambient temperature (24 h). The solution was washed with sodium carbonate 
(4×10 mL) and then the organic phase was dried (MgSO4), filtered, and the solvents were 
removed on a rotary evaporator at water aspirator pressure. Purification by 
chromatography (hexanes/EtOAc, 9:1) gave 7 (225 mg, 0.791 mmol, 79%) as a yellow 
solid. Mp 96–97 °C; 1H NMR: δ 8.77 (br s, 1H), 8.09 (dd, J=7.8, 1.8 Hz, 1H), 7.99 (dd, 
J=8.4, 1.8 Hz, 1H), 7.34 (t, J=7.8 Hz, 2H), 7.30–7.28 (m, 3H), 6.71 (t, J=7.8 Hz, 1H), 
4.16 (d, J=4.2 Hz, 2H), 3.88 (s, 3H); 13C NMR: δ 167.7, 145.3, 137.6, 137.3, 136.9, 
131.6, 128.9, 127.9, 127.9, 116.9, 114.7, 52.4, 51.0; IR (neat): 1699, 1577, 1490, 1259, 
1105 cm−1; Anal. Calcd for C15H14N2O4: C, 62.93; H, 4.93. Found: C, 63.28; H, 5.30. 
 
N-Benzyl-2-nitrobenzenamine (8) 
To a solution of 2-nitrobenzenamine (300 mg, 2.17 mmol), benzaldehyde (420 µL, 4.13), 
glacial acetic acid (750 µL, 13.1 mmol), and dichloromethane (10 mL) was added sodium 
triacetoxyborohydride (1.29 g, 6.09 mmol) and the reaction mixture was stirred at 
ambient temperature (90.5 h). Additional benzaldehyde (210 µL, 2.06 mmol) was added 
and the solution was stirred at ambient temperature (28.75 h). Additional sodium 
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triacetoxyborohydride (648 mg, 3.06 mmol) was added and the solution was stirred at 
ambient temperature (23.5 h). The mixture was diluted with  aqueous sodium bicarbonate 
(10 mL) and washed with EtOAc (4×10 mL). The combined organic phases were dried 
(MgSO4), filtered, and the solvents were removed on a rotary evaporator at water 
aspirator pressure. The crude product was purified by chromatography (hexanes then 
hexanes/EtOAc, 95:5) to give 8 (409 mg, 1.80 mmol, 83%) as an orange solid. Mp 73–
74 °C (lit.119 72 °C). 
 
N-4-Nitrobenzyl-2-nitrobenzenamine (9) 
A solution of 2-nitrobenzenamine (552 mg, 4.00 mmol), 4-nitrobenzaldehyde (605 mg, 
4.01 mmol), and benzene (50 mL) was heated at reflux (110 °C, 47 h followed by 130 °C 
for 67 h) while removing water via a Dean–Stark trap. After cooling to ambient 
temperature, dichloromethane (20 mL) and sodium triacetoxyborohydride (2.37 g, 
11.2 mmol) were added and the reaction mixture was stirred at ambient temperature 
(23.25 h). Workup as described for 8 gave after chromatography (hexanes/EtOAc, 9:1) 9 
(270 mg, 0.988 mmol, 25%) as a yellow solid. Mp 127–129 °C (lit.93 133–135 °C). 
 
N-Benzyl-5-chloro-2-nitrobenzenamine (10) 
5-Chloro-2-nitrobenzenamine (599 mg, 3.47 mmol), benzaldehyde (68 µL, 6.68 mmol), 
and acetic acid (1.2 mL, 21.0 mmol), in dichloromethane (20 mL) with sodium 
triacetoxyborohydride (2.07 g, 9.77 mmol), were reacted as described for 7. Additional 
benzaldehyde (340 µL, 3.34 mmol, after 19.75 h), sodium triacetoxyborohydride (1.03 g, 
4.86 mmol, after 20 h), benzaldehyde (340 µL, 3.34 mmol, after 26.5 h), and 
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triacetoxyborohydride (1.03 g, 4.86 mmol, after 27 h) were added, and the reaction 
mixture was stirred for an additional 20.25 h. Workup as described for 8 gave after 
chromatography (hexanes then hexanes/EtOAc, 98:2) 10 (322 mg, 1.23 mmol, 35%) as 
an orange solid. Mp 96–98 °C (lit.120 100–101 °C). 
 
N-(2-Propen-1-yl)-2-nitrophenylamine (11) 
A solution of 1-iodo-2-nitrobenzene (124 mg, 0.498 mmol), N-(2-propen-1-yl)amine 
(50 µL, 0.666 mmol), palladium diacetate (Pd(OAc)2, 11.7 mg, 0.052 mmol), 2,2′-
bis(diphenylphosphino)-1,1′-binaphthyl (binap, 47.1 mg, 0.076 mmol), and cesium 
carbonate (228 mg, 0.700 mmol) in toluene (6 mL) was stirred (30 min) under argon 
atmosphere followed by heating at 80 °C (44.75 h). The mixture was cooled to ambient 
temperature, diluted with EtOAc (6 mL), filtered (Celite), and the Celite was washed with 
a few milliliter of EtOAc. The solvents were removed on a rotary evaporator at water 
aspirator pressure and the crude product was purified by column chromatography on 
silica (hexanes/EtOAc, 9:1) to give 11 (72.2 mg, 0.405 mmol, 81%) as an orange oil. 
Analytical data are in complete agreement with published values90a. 
 
N-(4-Methoxybenzyl)-2-nitrobenzenamine (12) 
A solution of 2-bromo-1-nitrobenzene (230 mg, 1.14 mmol), 4-methoxybenzylamine 
(170 µL, 1.31 mmol), Pd(OAc)2 (23.6 mg, 0.105 mmol), binap (94.0 mg, 0.151 mmol), 
and cesium carbonate (460 mg, 1.41 mmol) in toluene (6 mL) was reacted, as described 
for 11 (rt, 30 min; 80 °C, 28.5 h), to give after purification by chromatography 
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(hexanes/EtOAc, 9:1) 12 (270 mg, 1.05 mmol, 92%) as a yellow solid. Mp 94–95 °C 
(lit.121 81–82 °C). 
 
N-Benzyl-4-methoxy-2-nitrobenzenamine (13) 
Reaction of 4-bromo-3-nitro-1-methoxybenzene (461 mg, 2.00 mmol), benzylamine 
(290 µL, 2.66 mmol), Pd(OAc)2 (45.1 mg, 0.201 mmol), binap (188 mg, 0.302 mmol), 
and cesium carbonate (914 mg, 2.81 mmol) in toluene (6 mL), as described for 11 
(30 min at rt, 16.5 h at 80 °C), gave after dilution, filtration, and chromatography 
(hexanes then hexanes/EtOAc, 98:2) 13 (380 mg, 1.48 mmol, 74%) as a red solid. Mp 
104–105 °C (lit.122 105–106 °C); 1H NMR: δ 8.35 (br s, 1H), 7.65 (d, J=2.4 Hz, 1H), 
7.37–7.33 (m, 4H), 7.29 (t, J=6.6 Hz, 1H), 7.08 (dd, J=9.6, 3.0 Hz, 1H), 6.78 (d, 
J=9.6 Hz, 1H), 4.54 (d, J=5.4 Hz, 2H), 3.78 (s, 3H); 13C NMR: δ 149.9, 141.1, 137.6, 
131.4, 128.9, 127.6, 127.1, 127.0, 115.6, 107.3, 55.9, 47.3; IR (neat): 1569, 1515, 1281, 
1031 cm−1; Anal. Calcd for C14H14N2O3: C, 65.11; H, 5.46. Found: C, 65.01; H, 5.73. 
 
N-Benzyl-N-methyl-4-methoxy-2-nitrobenzenamine (14) 
A solution of 2-bromo-5-methoxy-1-nitrobenzene (500 mg, 2.16 mmol), N-benzyl-N-
methyl amine (370 µL, 2.87 mmol), Pd(OAc)2 (49.3 mg, 0.220 mmol), binap (202 mg, 
0.325 mmol), and cesium carbonate (984 mg, 3.02 mmol) in toluene (6 mL), as described 
for 11 (30 min at rt, 19.75 h at 80 °C), gave after dilution, filtration, and chromatography 
(hexanes/EtOAc, 95:5) 14 (340 mg, 1.25 mmol, 58%) as a dark red oil. 1H NMR: δ 7.29–
7.27 (m, 4H), 7.22–7.20 (m, 2H), 7.11 (d, J=9.6 Hz, 1H), 6.98 (dd, J=9.0, 3.0 Hz, 1H), 
4.14 (s, 2H), 3.73 (s, 3H), 2.64 (s, 3H); 13C NMR: δ 154.0, 143.9, 139.7, 137.5, 128.2, 
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128.0, 127.1, 123.4, 119.8, 109.0, 60.2, 55.6, 41.1; IR (neat): 1519, 1496, 1452, 1292, 




Reaction of 2-iodo-4-methoxy-1-nitrobenzene (500 mg, 1.79 mmol), N-benzyl-N-methyl 
amine (300 µL, 2.33 mmol), Pd(OAc)2 (40.7 mg, 0.181 mmol), binap (168 mg, 
0.269 mmol), and cesium carbonate (819 mg, 2.51 mmol) in toluene (6 mL), as described 
for 11 (45.5 h at 80 °C, 23.25 h at 120 °C), gave after dilution, filtration, and 
chromatography (hexanes/EtOAc, 98:2) 15 (262 mg, 0.962 mmol, 54%) as a yellow 
solid. Mp 97–99 °C; 1H NMR: δ 7.85 (d, J=9.6 Hz, 1H), 7.32–7.22 (m, 5H), 6.45 (d, 
J=1.8 Hz, 1H), 6.38 (dd, J=9.6, 2.4 Hz, 1H), 4.33 (s, 2H), 3.74 (s, 3H), 2.74 (s, 3H); 13C 
NMR: δ 163.4, 148.3, 136.8, 133.8, 128.9, 128.4, 127.4, 127.2, 105.0, 104.0, 58.5, 55.5, 
40.3; IR (neat): 1613, 1567, 1501, 1450, 1415, 1216 cm−1; Anal. Calcd for C15H16N2O3: 
C, 66.16; H, 5.92. Found: C, 65.94; H, 6.22. 
 
N-Benzyl-2,4-dinitrobenzenamine (16) 
Reaction of 1-bromo-2,4-dinitrobenzene (494 mg, 2.00 mmol), benzylamine (290 µL, 
2.66 mmol), Pd(OAc)2 (45.5 mg, 0.203 mmol), binap (197 mg, 0.316 mmol), and cesium 
carbonate (914 mg, 2.81 mmol) in toluene (6 mL), as described for 11 (30 min at rt, 
19.5 h at 80 °C), gave after dilution, filtration, and chromatography (hexanes/EtOAc, 9:1 





Reaction of 2-bromo-5-methoxy-1-nitrobenzene (375 mg, 1.62 mmol), isoindoline 
(255 mg, 2.14 mmol), Pd(OAc)2 (36.2 mg, 0.161 mmol), binap (151 mg, 0.242 mmol), 
and cesium carbonate (738 mg, 2.27 mmol) in toluene (6 mL), as described for 11 
(30 min at rt, 19.5 h at 80 °C) gave after dilution, filtration, and chromatography 
(hexanes/EtOAc, 9:1) 17 (374 mg, 1.38 mmol, 85%) as a red solid. Mp 103–104 °C 
(lit.124 112 °C). 
 
2-(2-Nitro-1-phenyl)-1,2,3,4-tetrahydroisoquinoline (19) 
Reaction of 2-bromo-1-nitrobenzene (404 mg, 2.00 mmol), 1,2,3,4-
tetrahydroisoquinoline (330 µL, 2.64 mmol), Pd(OAc)2 (45.5 mg, 0.203 mmol), binap 
(187 mg, 0.301 mmol), and cesium carbonate (915 mg, 2.81 mmol) in toluene (6 mL), as 
described for 11 (6 h at rt, 40.75 h at 80 °C), gave after dilution, filtration, and 
chromatography (hexanes/EtOAc, 95:5) 19 (344 mg, 1.35 mmol, 68%) as an orange 
solid. Mp 98–100 °C (lit.125 100–102 °C). 
 
2-(2-Nitrophenyl)-2,3-dihydro-1H-benzo[de]isoquinoline (20) 
Reaction of 2-iodonitrobenzene (124 mg, 0.498 mmol), 2,3-dihydro-1H-
benzo[de]isoquinoline (109 mg, 0.644 mmol), Pd(OAc)2 (11.8 mg, 0.053 mmol), binap 
(46.7 mg, 0.075 mmol), and cesium carbonate (229 mg, 0.703 mmol) in toluene (6 mL), 
as described for 11 (30 min at rt, 91.25 h at 80 °C), gave after dilution, filtration, and 
chromatography (hexanes/EtOAc, 6:4) 20 (121 mg, 0.417 mmol, 84%) as a yellow solid. 
Mp 104–108 °C; 1H NMR: δ 7.77 (d, J=7.8 Hz, 1H), 7.71 (d, J=8.4 Hz, 2H), 7.41 (t, 
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J=7.8 Hz, 2H), 7.31 (t, J=8.4 Hz, 1H), 7.21 (d, J=6.6 Hz, 2H), 7.14 (d, J=9.0 Hz, 1H), 
6.96 (t, J=7.8 Hz, 1H), 4.63 (s, 4H); 13C NMR: δ 145.3, 143.3, 133.4, 132.1, 128.0, 126.6, 
126.0, 125.8, 121.8, 121.7, 121.7, 55.2; IR (neat): 1602, 1520, 1355, 1214, 802, 
752 cm−1; Anal. Calcd for C18H14N2O2: C, 74.47; H, 4.86. Found: C, 74.23; H, 5.23. 
 
N-Benzyl-N-(2-nitrophenyl)acetamide93 (25) 
To a solution of 8 (116 mg, 0.51 mmol) in acetic anhydride (1 ml) was added acetyl 
chloride (0.04 ml, 0.56 mmol) and H2SO4 (1 drop) with heating until 8 dissolved.  The 
resulting mixture was stirred at room temperature for 24 h.  To the reaction mixture was 
added H2O (5 ml) then extracted with EtOAc (3x5 ml).  The combined organic phase was 
dried (MgSO4) and the solvents were removed on a rotary evaporator at water aspirator 
pressure.  Purification by chromatography (hexanes/EtOAc, 7:3) gave 25 (126 mg, 
0.47 mmol, 92%). 
 
2-Ethenyl-1H-benzimidazole (26) 
To a threaded ACE Glass pressure tube were added 11 (72.2 mg, 0.405 mmol), 
bis(dibenzylideneacetone)palladium (Pd(dba)2, 14.1 mg, 0.025 mmol), and 1,10-
phenanthroline monohydrate (8.40 mg, 0.047 mmol) in DMF (6 mL). The tube was fitted 
with a pressure head and after the solution was saturated with CO (four cycles to 6 atm of 
CO) the reaction mixture was heated at 120 °C under CO (6 atm, 47 h). The mixture was 
diluted with EtOAc (10 mL) and washed with water (4×10 mL). The combined organic 
phases were dried (MgSO4), filtered, and the solvents were removed on a rotary 
evaporator at water aspirator pressure. Purification by chromatography (hexanes/EtOAc, 
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2:8) gave 26 (27.1 mg, 0.188 mmol, 46%) as a pale brown solid. Mp 149–153 °C (lit.79 
184 °C). 
 
Methyl 2-ethenyl-1H-benzimidazole-4-carboxylate (27) 
Reaction of 5 (37.8 mg, 0.160 mmol), Pd(dba)2 (7.30 mg, 0.013 mmol), and 1,10-
phenanthroline monohydrate (4.0 mg, 0.022 mmol) in DMF (6 mL), as described for 26 
(CO, 120 °C, 70.5 h), gave after extraction and chromatography (hexanes/EtOAc, 7:3) 27 
(24.1 mg, 0.119 mmol, 74%) as a red solid. Mp 64–71 °C; 1H NMR: δ 7.94 (dd, J=7.8, 
0.6 Hz, 1H), 7.88 (dd, J=7.8, 1.2 Hz, 1H), 7.29 (t, J=7.8 Hz, 1H), 6.85 (dd, J=18.0, 
11.4 Hz, 1H), 6.26 (d, J=18.0 Hz, 1H), 5.73 (d, J=11.4 Hz, 1H), 3.98 (s, 3H); 13C NMR: 
δ 167.0, 151.3, 144.5, 134.4, 126.1, 125.0, 125.0, 121.9, 121.7, 113.2, 52.1; IR (neat): 
1702, 1431, 1291, 1137, 931 cm−1; HRMS calcd for C11H11N2O2 (M+H+): 203.0821, 
found: 203.0815. 
 
N-(2-Propen-1-yl) 2-ethenyl-1H-benzimidazole-4-carboxamide (28) 
Reaction of 6 (261 mg, 1.00 mmol), Pd(dba)2 (34.8 mg, 0.061 mmol), and 1,10-
phenanthroline monohydrate (21.7 mg, 0.120 mmol) in DMF, (6 mL) as described for 26 
(CO, 120 °C, 47 h), gave after extraction and chromatography (hexanes/EtOAc, 6:4) 28 
(50.1 mg, 0.221 mmol, 22%) as a 7:1 mixture of rotamers as a pale yellow solid. Mp 
192–195 °C; major rotamer: 1H NMR (DMSO-d6): δ 13.11 (br s, 1H), 9.91 (br s, 1H), 
7.86 (d, J=7.8 Hz, 1H), 7.68 (d, J=7.8 Hz, 1H), 7.33 (t, J=7.8 Hz, 1H), 6.85 (dd, J=18.0, 
11.4 Hz, 1H), 6.38 (d, J=14.4 Hz, 1H), 6.01 (10-line ddt, J=17.4, 10.8, 5.4 Hz, 1H), 5.80 
(d, J=11.4 Hz, 1H), 5.30 (dd, J=17.4, 1.2 Hz, 1H), 5.15 (dd, J=10.2, 1.2 Hz, 1H), 4.09 (t, 
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J=5.4 Hz, 2H); 13C NMR: δ 164.3, 151.2, 140.8, 135.3, 134.5, 126.1, 122.8, 122.6, 122.5, 
122.0, 115.0, 114.8, 41.1; IR (neat): 1637, 1610, 1554, 1429, 1251 cm−1; Anal. Calcd for 
C13H13N2O: C, 68.70; H, 5.77. Found: C, 68.81; H, 6.01. Minor rotamer: 1H NMR 
(DMSO-d6): δ 12.42 (br s, 1H), 8.81 (br s, 1H), 7.73 (t, J=8.4 Hz, 2H), 7.22 (t, J=7.8 Hz, 
1H), 6.96 (dd, J=18.0, 11.4 Hz, 1H), 6.43 (d, J=17.4 Hz, 1H), 5.60–5.92 (m, 1H), 5.62 (d, 
J=11.4 Hz, 1H), 5.21 (d, J=17.4 Hz, 1H), 5.11 (d, J=10.2 Hz, 1H), 3.98 (br s, 2H). 
 
2-(2-Phenyl-1-ethenyl)-1H-benzimidazole (29) 
Reaction of 21 (267 mg, 1.05 mmol), Pd(dba)2 (37.0 mg, 0.064 mmol), and 1,10-
phenanthroline monohydrate (22.8 mg, 0.127 mmol) in DMF (6 mL), as described for 26 
(CO, 120 °C, 92.75 h), gave after extraction and chromatography (hexanes/EtOAc, 6:4) 




Reaction of 8 (114 mg, 0.502 mmol), Pd(dba)2 (17.7 mg, 0.031 mmol), and 1,10-
phenanthroline monohydrate (10.4 mg, 0.058 mmol) and DMF (6 mL), as described for 
26 (CO, 120 °C, 139.75 h), gave after extraction and chromatography (hexanes/EtOAc, 








Reaction of 12 (250 mg, 0.968 mmol), Pd(dba)2 (33.7 mg, 0.059 mmol), and 1,10-
phenanthroline monohydrate (21.3 mg, 0.118 mmol) in DMF (6 mL), as described for 26 
(CO, 120 °C, 65.5 h), gave after extraction and chromatography (hexanes/EtOAc, in 
order 8:2, 1:1) 31 (121 mg, 0.540 mmol, 56%) as a pale brown solid. Mp 222–225 °C 
(lit.76 222–225 °C). 
 
5-Methoxy-2-phenyl-1H-benzimidazole (33) 
Reaction of 13 (128 mg, 0.498 mmol), Pd(dba)2 (17.7 mg, 0.031 mmol), 1,10-
phenanthroline monohydrate (10.7 mg, 0.060 mmol) in DMF (6 mL), as described for 26 
(CO, 120 °C, 193.75 h), gave after extraction and chromatography (hexanes/EtOAc, 7:3) 




Reaction of 14 (136 mg, 0.499 mmol), Pd(dba)2 (17.8 mg, 0.031 mmol), and 1,10-
phenanthroline monohydrate (10.9 mg, 0.061 mmol) in DMF (6 mL), as described for 26 
(CO, 120 °C, 67.75 h), gave after extraction and chromatography (hexanes/EtOAc, 9:1 
then 1:1) 35 (61.4 mg, 0.258 mmol, 52%) as a white solid129. Mp 123–126 °C; 1H NMR: 
δ 7.75 (d, J=7.8 Hz, 2H), 7.53–7.48 (m, 3H), 7.30 (s, 1H), 7.27 (d, J=9.0 Hz, 1H), 6.98 
(d, J=8.4 Hz, 1H), 3.87 (s, 3H), 3.84 (s, 3H); 13C NMR: δ 156.4, 153.9, 143.6, 131.3, 
130.2, 129.6, 129.3, 128.6, 112.8, 110.0, 101.9, 55.8, 31.7; IR (neat): 1467, 1158, 1025, 
64 
 
833, 803, 770 cm−1; Anal. Calcd for C15H14N2O: C, 75.61; H, 5.92. Found: C, 75.49; H, 
6.42; HRMS calcd for C15H15N2O (M+H+): 239.1184, found: 239.1179. 
 
6-Methoxy-1-methyl-2-phenyl-1H-benzimidazole (36) 
Reaction of 15 (134 mg, 0.492 mmol), Pd(dba)2 (17.4 mg, 0.030 mmol), and 1,10-
phenanthroline monohydrate (10.6 mg, 0.059 mmol) in DMF (6 mL), as described for 26 
(CO, 120 °C, 115.5 h), gave after extraction and chromatography (hexanes/EtOAc, in 
order 9:1, 7:3, 3:7) 15 (38.1 mg, 0.140 mmol, 28%) followed by 36 (70.6 mg, 
0.296 mmol, 60%) as a white solid. Mp 145–147 °C; 1H NMR: δ 7.70 (t, J=7.2 Hz, 3H), 
7.48–7.43 (m, 3H), 6.93 (dd, J=9.0, 2.4 Hz, 1H), 6.78 (s, 1H), 3.85 (s, 3H), 3.74 (s, 3H); 
13C NMR: δ 156.6, 152.8, 137.3, 130.2, 129.3, 129.1, 128.5, 120.1, 111.5, 93.1, 55.7, 
31.5; IR (neat): 1462, 1216, 1084, 1023, 809 cm−1; Anal. Calcd for C15H14N2O: C, 75.61; 




Reaction of N-benzyl-4-chloro-2-nitrobenzenamine (23)130 (131 mg, 0.499 mmol), 
Pd(dba)2 (17.2 mg, 0.030 mmol), and 1,10-phenanthroline monohydrate (11.0 mg, 
0.061 mmol) in DMF (6 mL), as described for 26 (CO, 120 °C, 46.5 h), gave after 
extraction and chromatography (hexanes/EtOAc, 9:1 then 1:1) 37 (72.9 mg, 0.319 mmol, 




Alternative procedure: Reaction of 10 (131 mg, 0.499 mmol), Pd(dba)2 (18.0 mg, 
0.031 mmol), and 1,10-phenanthroline monohydrate (11.6 mg, 0.064 mmol) in DMF 
(6 mL), as described for 26 (CO, 120 °C, 74 h), gave after extraction and chromatography 
(hexanes/EtOAc, 1:1) 37 (67.4 mg, 0.295 mmol, 59%) as a pale brown solid. 
 
Methyl 2-phenyl-1H-benzimidazole-4-carboxylate (38) 
Reaction of 7 (143 mg, 0.503 mmol), Pd(dba)2 (17.6 mg, 0.031 mmol), and 1,10-
phenanthroline monohydrate (11.0 mg, 0.061 mmol) in DMF (6 mL), as described for 26 
(CO, 120 °C, 139.5 h), gave after extraction and chromatography (hexanes/EtOAc, 9:1 
then 7:3) 38 (56.7 mg, 0.225 mmol, 45%) as a pale brown solid. Mp 123–126 °C (lit.131 
125–127 °C). 
 
Alternative procedure: Reaction of 7 (99.3 mg, 0.349 mmol), Pd(dba)2 (12.6 mg, 
0.022 mmol), 1,10-phenanthroline monohydrate (7.8 mg, 0.043 mmol), and 1,3-
bis(diphenylphosphino)propane (8.9 mg, 0.022 mmol) in DMF (5 mL), as described for 
26 (CO, 120 °C, 138.5 h), gave after extraction and chromatography (hexanes/EtOAc, 9:1 
then 7:3) 38 (47.4 mg, 0.188 mmol, 54%) as a pale brown solid. 
 
7-Methoxy-11H-isoindolo[2,1-a]benzimidazole (41) 
Reaction of 17 (113 mg, 0.418 mmol), Pd(dba)2 (15.1 mg, 0.026 mmol), and 1,10-
phenanthroline monohydrate (8.9 mg, 0.050 mmol) in DMF (6 mL), as described for 26 
(CO, 120 °C, 76 h), gave after extraction and chromatography (hexanes/EtOAc, 7:3) 41 
(34.3 mg, approximately 90% pure by 1H NMR)132. Spectral data from impure 41: 1H 
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NMR: δ 7.96 (d, J=7.2 Hz, 1H), 7.49 (d, J=7.2 Hz, 1H), 7.46 (t, J=7.2 Hz, 1H), 7.41 (dt, 
J=7.2, 1.2 Hz, 1H), 7.26 (d, J=2.4 Hz, 1H), 7.24 (dd, J=7.2, 1.8 Hz, 1H), 6.87 (dd, J=6.6, 
1.8 Hz, 1H), 4.91 (s, 2H), 3.84 (s, 3H); 13C NMR: δ 158.7, 156.1, 149.1, 143.3, 129.4, 
129.2, 128.6, 127.3, 123.9, 121.7, 112.6, 109.8, 103.2, 55.8, 47.3; HRMS calcd for 
C15H13N2O (M+H+): 237.1028, found: 237.1023. 
 
5,6-Dihydrobenz[4,5]imidazo[2,1-a]isoquinoline (43) and benz[4,5]imidazo[2,1-
a]isoquinoline (44) 
Reaction of 19 (127 mg, 0.499 mmol), Pd(dba)2 (17.3 mg, 0.030 mmol), and 1,10-
phenanthroline monohydrate (11.1 mg, 0.062 mmol) in DMF (6 mL), as described for 26 
(CO, 120 °C, 67.5 h), gave after extraction and chromatography (hexanes/EtOAc, 9:1) 44 
(6.6 mg, 0.030 mmol, 6%) as a pale yellow solid followed by 43 (48.9 mg, 0.222 mmol, 
44%) as a pale brown solid129. Data for 44: mp 107–108 °C (lit.133,134 129–130 °C). Data 
for 43: mp 148–149 °C; 1H NMR: δ 8.30 (dd, J=7.8, 1.8 Hz, 1H), 7.84–7.81 (m, 1H), 
7.42–7.34 (m, 3H), 7.31–7.25 (m, 3H), 4.32 (t, J=7.2 Hz, 2H), 3.27 (t, J=7.2 Hz, 2H); 13C 
NMR: δ 149.1, 144.0, 134.7, 134.2, 130.1, 128.0, 127.7, 126.7, 125.6, 122.6, 122.4, 
119.8, 109.0, 40.4, 28.2; IR (neat): 1482, 1448, 1326, 775, 734 cm−1; Anal. Calcd for 
C15H12N2: C, 81.79; H, 5.49. Found: C, 81.49; H, 5.92. 
 
7H-Benzimidazo[2,1-a]benz[de]isoquinoline (45) 
Reaction of 20 (102 mg, 0.351 mmol), Pd(dba)2 (11.3 mg, 0.020 mmol), and 1,10-
phenanthroline monohydrate (8.0 mg, 0.044 mmol) in DMF (6 mL), as described above 
for 26 (CO, 120 °C, 112 h), gave after extraction and chromatography (hexanes/EtOAc, 
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2-Amino-3-nitrotoluene (11.9 g, 77.2 mmol) was dissolved in 60 ml H2O and 30 ml of 
1,4-dioxane and heated to reflux.  Hydrobromic acid (34 ml, 48%) was added dropwise 
over a 20 min. period, after which the mixture was heated at reflux an additional 15 min.  
The reaction was cooled to 0 ºC and sodium nitrite (5.34 g, 77.4 mmol) in 40 ml of H2O 
was added dropwise over a 30 min. period followed by stirring 15 min. at 0 ºC.  The 
mixture was added dropwise to a stirring solution of copper(I) bromide (11.2 g, 78.1 
mmol) in 60 ml  H2O and 34 ml HBr (48%) at 0 ºC.  The reaction was stirred for 15 min. 
at 0 ºC, warmed to 60 ºC, stirred 15 min., then cooled to room temperature, and stirred 
overnight.  The reaction mixture was transferred to a separatory funnel and extracted with 
diethyl ether (4x300 ml).  The combined organic phases were dried (MgSO4), filtered, 
and the solvents were removed on a rotary evaporator at water aspirator pressure. 
Purification by chromatography (hexanes/EtOAc, in order 98:2, 95:5, 9:1, 8:2) gave 47 
(5.45 g, 25.0 mmol, 32%) as a yellow solid. 
 
(R)-1-Methyl-2,5-dioxopyrrolidin-yl acetate102 (49) 
A mixture of D-malic acid (5.31 g, 39.6 mmol) and AcCl (13 ml) was heated at 45 ºC for 
1 h. then another 15 ml of AcCl was added and heated for another 4 h.  The solvent was 
removed in vacuo, the residue was dissolved in CH2Cl2 (90 ml) and cooled to -20 ºC.  To 
this was added a solution of methanamine (1.5 g, 48.3) in CH2Cl2 (60 ml) at -78 ºC.  The 
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resulting mixture was allowed to warm to room temperature and stirred for 5.5 h.  The 
solvents were removed on a rotary evaporator at water aspirator pressure and AcCl (50 
ml) was added.  The resulting mixture stirred at 50 ºC for 11 h.  The AcCl was removed 
and purification by chromatography (hexanes/EtOAc, 1:1) gave 49 (6.55 g, 38.3 mmol, 
97%) as a clear liquid. 
 
(R)-3-Hydroxy-1-methylpyrrolidine-2,5-dione102 (50) 
To a solution of 49 (6.55 g, 38.3 mmol) in absolute ethanol (50 ml) was bubbled dry HCl 
gas at 50 ºC for 1 h.  The solvent was removed to dryness and the residue was purified by 
chromatography (hexanes/EtOAc, 1:3) giving 50 (4.45 g, 34.5, 90%) as a white solid. 
 
(R)-3-[(tert-Butyldimethylsilyl)oxy]-1-methylpyrrolidine-2,5-dione102 (51) 
To a stirred solution of 50 (4.28 g, 33.2 mmol) in DMF (10 ml) was added tert-
butylchlorodimethylsilane (6.03 g, 40.0 mmol) and imidazole (2.38 g, 35.0 mmol).  The 
mixture was stirred at room temperature for 23.75 h. then H2O (30 ml) was added.  The 
mixture was extracted with EtOAc (4x15 ml), dried (MgSO4), filtered, and the solvents 
were removed on a rotary evaporator at water aspirator pressure giving 51 (7.68 g, 
31.6 mmol, 95%) as a white solid. 
 
(R)-4-[(tert-Butyldimethylsilyl)oxy]-5-hydroxy-1-methylpyrrolidin-2-one102 (52) 
To a solution of 51 (5.65 g, 23.2 mmol) in MeOH (20 ml) was added sodium borohydride 
(2.63 g, 69.5 mmol) in one portion at -10 ºC.  After stirring for 10 min., saturated NH4Cl 
(20 ml) was added and the solution was extracted with EtOAc (4x10 ml).  The combined 
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organic phases were dried (MgSO4), filtered, and the solvents were removed on a rotary 




To a suspension of NaH (80%, 651 mg, 27.1 mmol) in THF (8 ml) at 0 ºC was dropwise 
added a solution of 52 (5.29 g, 21.6 mmol) in THF (8 ml).  After stirring 0.5 h., methyl 
iodide (2.15 ml, 34.5 mmol) was added.  The mixture was allowed to warm to room 
temperature and stirred for 2 h.  The solvent was removed on a rotary evaporator at water 
aspirator pressure and purification by chromatography (hexanes/EtOAc, 2:1) gave 53 
(4.43 g, 17.1 mmol, 79%) as a yellow liquid. 
 
(4R, 5S)-5-Allyl-4-[(tert-butyldimethylsilyl)oxy]-1-methylpyrrolidin-2-one (54) and 
(4R, 5R)-5-allyl-4-[(tert-butyldimethylsilyl)oxy]-1-methylpyrrolidin-2-one102 (55)  
A solution of 53 (1.01 g, 3.89 mmol) and allyltrimethylsilane (2.45 ml, 15.4 mmol) in 
CH2Cl2 (20 ml) at -78 ºC was stirred for 15 min.  TiCl4 (0.85 ml, 7.7 mmol) in CH2Cl2 
(10 ml) was slowly added and after 5 min. the cooling bath was removed and the mixture 
was stirred for 2 h. then quenched by pouring into a stirred slurry of Na2CO3·10H2O 
(13g) in CH2Cl2 (15 ml).  After 15 min., MgSO4 was added and the mixture was 0.5 h.  
The filtered organic phase was removed on a rotary evaporator at water aspirator pressure 
and purification by chromatography (hexanes/EtOAc, 1:1) gave 54 (156 mg, 0.58 mmol, 




(4R, 5S)-5-Allyl-4-hydroxy-1-methylpyrrolidin-2-one102 (56) 
To a solution of 54 (134 mg, 0.50 mmol) was added dropwise a solution of 
tetrabutylammonium fluoride (1 M in THF, 0.60 ml).  After stirring for 12.5 h., the 
solvents were removed on a rotary evaporator at water aspirator pressure and purification 
by chromatography (EtOAc, EtOAc/ MeOH, 95:5, MeOH) gave 56 (100 mg, 0.64 mmol, 
quant.) 
 
(4R, 5R)-5-Allyl-4-hydroxy-1-methylpyrrolidin-2-one102 (57) 
To a solution of 55 (353 mg, 1.31 mmol) was added dropwise a solution of 
tetrabutylammonium fluoride (1 M in THF, 1.57 ml).  After stirring for 7 h., the solvents 
were removed on a rotary evaporator at water aspirator pressure and purification by 
chromatography (EtOAc, EtOAc/ MeOH, 9:1) gave 57 (197 mg, 1.27 mmol, 97%). 
 
(4R, 5R)-5-Allyl-4-methanesulfoxy-2-pyrrolidone136 (58) 
To a solution of 57 (155 mg, 1.0 mmol) in 10 ml CH2Cl2 were added at 0 ºC 
methanesulfonyl chloride (85 µl, 1.1 mmol) and triethylamine (185 µl, 1.3 mmol).  The 
solution was stirred at 0 ºC for 1 h. and was then allowed to warm to rt.  After stirring 
overnight, water (10 ml) was added and the mixture was extracted with CH2Cl2 (4x10 
ml).  The crude solid was redissolved in 10 ml CH2Cl2 and methanesulfonyl chloride (85 
µl, 1.1 mmol) and triethylamine (185 µl, 1.3 mmol) were added at 0 ºC.  The solution 
was stirred at 0 ºC for 1 h. and was then allowed to warm to rt.  After stirring overnight, 
water (10 ml) was added and the mixture was extracted with CH2Cl2 (4x10 ml).  The 
combined organic phases were dried (MgSO4), filtered, and the solvents were removed 
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on a rotary evaporator at water aspirator pressure. Purification by chromatography 
(EtOAc then EtOAc/MeOH, in order 95:5, 8:2, then MeOH) gave 58 (159 mg, 
0.68 mmol, 68%). 
 
(R)-Diethyl 2-(tetrahydro-2H-pyran-2-yloxy)succinate103 (59) 
Dihydropyran (12.3 ml, 134.8 mmol) was added to a solution of D-malic acid diethyl 
ester (8.3 g, 43.6 mmol) and pyridinium p-toluenesulfonate (1.2 g, 4.8 mmol) in CH2Cl2 
(220 ml).  After stirring (rt) for 4 h., the reaction mixture was diluted with CH2Cl2 (100 
ml), washed with half-saturated brine (2x100 ml), dried (MgSO4), and the solvents were 
removed on a rotary evaporator at water aspirator pressure.  Purification by 
chromatography (hexanes/EtOAc 7:3) gave 59 (11.9 g, 43.4 mmol, quant.). 
 
(R)-2-(Tetrahydro-2H-pyran-2-yloxy)butane-1,4-diol103 (60) 
A suspension of lithium aluminum hydride (1.3 g, 34.3 mmol) in 30 ml of THF was 
warmed at 55 ºC for 1 h.  Compound 59 (4.7 g, 17.1 mmol) in 15 ml THF was added 
dropwise and the resulting mixture was stirred at 55 ºC for 24 h. before cautious, 
sequential addition of water (2 ml), 10% NaOH (3 ml), and water (2 ml).  After filtration 
(diethyl ether wash), the filtrate was dried (MgSO4) and the solvents were removed in 
vacuo, affording 60 (2.7 g, 14.2 mmol, 83%). 
 
(R)-2-(Tetrahydro-2H-pyran-2-yloxy)butane-1,4-dimethanesulfonate103 (61) 
A solution of 60 (2.7 g, 14.2 mmol) in CH2Cl2 (55 ml) cooled to -15 ºC was treated 
sequentially with triethylamine (7.25 ml, 52.0 mmol) and methanesulfonyl chloride (3.7 
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ml, 47.8 mmol).  After 45 min. at -15 ºC the reaction mixture was poured over crushed 
ice and stirred for 5 min. before the organic layer was washed 5% HCl (50 ml), saturated 
NaHCO3 (50 ml), and H2O (50 ml), dried (MgSO4), and the solvents were removed on a 
rotary evaporator at water aspirator pressure.  Purification by chromatography (diethyl 
ether) gave 61 (1.96 g, 5.7 mmol, 40%). Starting material (60, 0.97 g) was also 
recovered. 
 
(R)-1,2,4-Butanetriol 1,4-bis(methanesulfonate)103 (62) 
A solution of 61 (3.8 g, 11.0 mmol) in absolute ethanol (20 ml) containing 0.3 ml of 
methanesulfonic acid was warmed at 50 ºC for 2 h.  The cooled mixture was stirred at 0 
ºC for 16 h. and filtered (cold EtOH wash), affording 62 (2.3 g, 8.3 mmol, 75%). 
 
(2R, 3R)-2-Allyl-1-methylpyrrolidin-3-ol137 (63) 
To a solution of 57 (284 mg, 1.8 mmol) in THF (8 ml) was added LiAlH4 (514 mg, 13.5 
mmol).  The suspension was stirred at 65 ºC for 19 h., then cooled to room temperature 
and H2O (2 ml), 3M aqueous solution of NaOH (2 ml), and H2O (2 ml) were added 
successively.  The mixture was extracted with EtOAc (3x25 ml), dried (MgSO4), and the 
solvents were removed on a rotary evaporator at water aspirator pressure to give crude 63 
(217 mg, 1.54 mmol, 86%).  1H NMR δ 5.90 (ddt, J=17.4, 9.6, 6.6 Hz, 1H), 5.16 (dq, 
J=17.4, 1.8 Hz, 1H), 5.06 (dpent, J=10.2, 1.2 Hz, 1H), 4.13 (ddd, J=7.2, 4.8, 2.4 Hz, 1H), 
3.73 (br s, 1H), 3.15 (dt, J=9.0, 3.0 Hz, 1H), 2.34-2.40 (m, 1H), 2.30-2.33 (m, 1H), 2.28 
(s, 3H), 2.18 (dddd, J=13.8, 9.6, 7.2, 3.0 Hz, 1H), 2.02-2.07 (m, 1H), 1.93 (dt, J=9.6, 4.6 
Hz, 1H), 1.69 (ddt, J=13.8, 9.0, 1.8 Hz, 1H);  13C δ 135.7 (-), 116.5 (+), 72.1 (-), 70.9 (-), 
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54.6 (+), 40.1 (-), 33.0 (+), 31.7 (+);  IR (neat) 3366, 2944, 2787, 1455, 1128 cm-1;  [α]25D 
=  -95.4 ±1.2 (c = 1.0, CHCl3);  HRMS (ESI) calcd for C8H15NO (M+H+) 142.12326, 
found 142.12264. 
 
(2S, 4R)-Methyl 4-hydroxypyrrolidine-2-carboxylate104 (64) 
To a stirred suspension of trans-4-hydroxy-L-proline (99.7 g, 0.76 mol) in methanol (400 
ml) at 0 ºC was added thionyl chloride (60 ml, 0.82 mmol).  The reaction mixture was 
stirred at 0 ºC for 1 h. then refluxed for 38.75 h.  The reaction mixture was allowed to 
cool and then precipitated with diethyl ether.  The precipitate was collected by filtration 
and washed with diethyl ether to give 64 (122.5 g, 0.68 mol, 89%) as a white solid. 
 
(2S, 4R)-1-tert-Butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate105 (65) 
To a suspension of 64 (38.1 g, 0.21 mol) and CH2Cl2 (300 ml) was added triethylamine 
(88 ml, 0.63 mol), and the system was immersed in an ice-salt bath.  To the mixture was 
added di-tert-butyl dicarbonate (50.1 g, 0.23 mol), and the reaction mixture was stirred 
for 20.5 h. during which time the ice bath expired.  The reaction mixture was washed 
with 1 M H3PO4 (2x150 ml) and saturated NaHCO3 (2x150ml), dried (MgSO4), and the 
solvents were removed on a rotary evaporator at water aspirator pressure giving 65 (50.7 









To a stirring solution of 65 (50.0 g, 0.20 mol) and DMF (80 ml) were added imidazole 
(28.9 g, 0.42 mol) and tert-butylchlorodimethylsilane (34.0 g, 0.23 mol).  The reaction 
mixture was stirred at room temperature for 1.5 h., diluted with diethyl ether (150 ml), 
and washed with H2O (150 ml), 1 M H3PO4 (150 ml), and saturated NaHCO3 (150 ml).  
The ether solution was dried (MgSO4) and the solvents were removed on a rotary 
evaporator at water aspirator pressure giving 66 (71.8 g, 0.20 mol, quant.). 
 
(2S, 4R)-1-(tert-Butyoxycarbonyl)-4-[(tert-butyldimethylsilyl)oxy]-2-
(hydroxymethyl)pyrrolidine106 (67)  
Lithium chloride (128 mg, 3.02 mmol) and NaBH4 (118 mg, 3.12 mmol) were added to a 
solution of 66 (307 mg, 0.85 mmol) in THF (0.5 ml) and MeOH (0.5 ml) at room 
temperature.  After stirring for 22 h., the mixture was concentrated, EtOAc (1 ml) was 
added to the residue and washed with 10% HCl (5 ml).  The aqueous layer was extracted 
with EtOAc (2x1 ml) and the combined organic phases were washed with NaHCO3 (5 
ml) and brine (5 ml).  The organic layer was dried (MgSO4), and the solvents were 










To a solution of 67 (2.0 g, 6.0 mmol) and CH2Cl2 (5 ml) was added triethylamine (1.7 ml, 
12.2 mmol).  The system was cooled in an ice-salt bath and methanesulfonyl chloride was 
added via an addition funnel.  The reaction mixture was stirred for 16.5 h., during which 
the ice bath expired.  The reaction mixture was partitioned between EtOAc (15 ml) and 
H2O (15 ml).  The organic phase was washed 1 M H3PO4 (30 ml), and saturated NaHCO3 
(30 ml), dried (MgSO4), and the solvents were removed on a rotary evaporator at water 
aspirator pressure.  The crude product was dissolved in THF (15 ml) and cooled in an ice 
bath and lithium triethylborohydride in THF (1.0 M solution, 24 ml) was added.  The 
cold bath was removed and the reaction mixture was stirred at room temperature for 3 h.  
The reaction mixture was diluted with EtOAc (15 ml) and washed with H2O (30 ml), 1 M 
H3PO4 (30 ml), saturated NaHCO3 (30 ml), and brine (30 ml).  The organic phase was 
dried (MgSO4) and the solvents were removed on a rotary evaporator at water aspirator 




A solution of 69 (219 mg, 0.69 mmol) in EtOAc (3 ml) was added to a mixture of 
RuO2·xH2O (12.5 mg, 0.09 mmol) and 10% NaIO4 (4 ml).  The solution was stirred 
vigorously for 3 h. at room temperature.  The layers were separated and the aqueous layer 
was extracted with EtOAc (2x3 ml).  The combined extracts was treated with 2-propanol 
(2 drops) and the precipitated solid was filtered off.  The filtrate was washed with brine 
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(3x1 ml), dried (MgSO4), and the solvents were removed on a rotary evaporator at water 
aspirator pressure.  Purification by chromatography (hexanes/EtOAc, 9:1) gave 70 




Lithium triethylborohydride in THF (1.0 M solution, 1.52 ml) was added to a solution of 
70 (0.42 mg, 1.27 mmol) in THF (5 ml) at -78 ºC.  After 30 min., the reaction was 
quenched with saturated aqueous NaHCO3 (10 ml) and the mixture was allowed to warm 
to room temperature.  The mixture was extracted with EtOAc (2x10 ml), dried (MgSO4) 
and the solvents were removed on a rotary evaporator at water aspirator pressure.  The 
crude product was dissolved in methanol (5 ml), pyridinium p-toluenesulfonate (27.8 mg, 
0.11 mmol) was added, and the reaction mixture was stirred for 15.5 h. at room 
temperature.  The mixture was diluted with EtOAc (10 ml) and the organic layer was 
washed successively with 10% citric acid (10 ml), saturated NaHCO3 (10 ml), and brine 
(10 ml).  The organic phase was dried (MgSO4) and the solvents were removed on a 
rotary evaporator at water aspirator pressure.  Purification by chromatography 
(hexanes/EtOAc, 6:1) gave 71 (376 mg, 1.09 mmol, 86%) as a mixture of isomers. 
 
(3R, 5R)-2-Allyl-3-[(tert-butyldimethylsilyl)oxy]-methylpyrrolidine102 (72)  
A solution of 71 (376 mg, 1.09 mmol) and allyltrimethylsilane (0.69 ml, 4.34 mmol) in 
CH2Cl2 (15 ml) at -78 ºC was stirred for 15 min.  TiCl4 (0.24 ml, 2.2 mmol) in CH2Cl2 (5 
ml) was slowly added and after 5 min. the cooling bath was removed and the mixture was 
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stirred for 2.5 h. then quenched by pouring into a stirred slurry of Na2CO3·10H2O (13g) 
in CH2Cl2 (15 ml).  After 15 min., MgSO4 was added and the mixture was 0.5 h.  The 
filtered organic phase was removed on a rotary evaporator at water aspirator pressure 
giving the crude mixture of isomers 72 (225 mg, 0.88 mmol, 81%). 
 
Spectral data for major rotamer of 72 
1H NMR δ 5.82 (ddt, J=16.8, 10.2, 6.6 Hz, 1H), 5.09 (d, J=17.4 Hz, 1H), 5.02 (d, J=10.2 
Hz, 1H), 4.20 (s, 1H), 3.58 (dt, J=14.4, 7.2 Hz, 1H), 3.13 (dt, J=7.1, 3.4 Hz, 1H), 2.33 
(pent, J=6.6 Hz, 1H), 2.26 (pent, J=7.2 Hz, 1H), 1.92 (dd, J=12.6, 6.6 Hz, 1H), 1.49 (ddd, 
J=13.2, 9.0, 4.8 Hz, 1H), 1.18 (d, J=6.6 Hz, 3H), 0.88 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H);  
13C δ 136.0 (-), 116.5 (+), 73.9 (-), 62.9 (-), 51.3 (-), 43.8 (+), 33.7 (+), 25.8 (-), 22.1 (-), 
18.0 (+), -4.4 (-), -5.0 (-). 
 
Partial spectral data for minor rotamer of 72 
1H NMR δ 3.87 (pent, J=4.2 Hz, 1H), 3.37 (ddd, J=15.0, 12.6, 6.0 Hz, 2H), 2.95 (dt, 
J=7.6, 5.3 Hz, 1H), 2.14 (pent, J=7.4 Hz, 1H), 1.75 (ddd, J=13.2, 6.6, 3.6 Hz, 1H), 1.15 
(d, J=6.6 Hz, 3H), 0.87 (s, 9H), 0.03 (s, 3H), 0.03 (s, 3H);  13C δ 135.7 (-), 116.9 (+), 67.0 
(-), 52.3 (-), 43.5 (+), 38.3 (+), 21.3 (-), 18.0 (+), -4.5 (-), -4.7 (-). 
 
(3R, 5R)-2-Allyl-1-(tert-butoxycarbonyl)-3-[(tert-butyldimethylsilyl)oxy]-5-
methylpyrrolidine105 (73)  
To a suspension of 72 (497 mg, 1.95 mmol) and CH2Cl2 (5 ml) was added triethylamine 
(0.81 ml, 5.81 mmol), and the system was immersed in an ice-salt bath.  To the mixture 
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was added di-tert-butyl dicarbonate (479 mg, 2.19 mmol), and the reaction mixture was 
stirred for 22 h. during which time the ice bath expired.  The reaction mixture was 
washed with 1 M H3PO4 (2x5 ml) and saturated NaHCO3 (2x5ml), dried (MgSO4), and 
the solvents were removed on a rotary evaporator at water aspirator pressure giving 73 
(625 mg, 1.76 mmol, 90%). 
 
Spectral data for major rotamer of 73 
1H NMR δ 5.86 (pent, J=8.0 Hz, 1H), 5.02 (d, J=18.6 Hz, 1H), 4.95 (d, J=9.6 Hz, 1H), 
4.43-4.45 (m, 1H), 3.76-4.03 (m, 2H), 2.49-2.61 (m, 1H), 2.24-2.26 (m, 1H), 1.93-2.08 
(m, 1H), 1.65-1.69 (m, 1H), 1.47 (s, 9H), 1.19 (d, J=6.0 Hz, 3H), 0.90 (s, 9H), 0.67 (s, 
6H). 
 
Partial spectral data for minor rotamer of 73 
1H NMR δ 5.78 (pent, J=8.6 Hz, 1H), 1.45 (s, 9H), 1.15 (d, J=6.0 Hz, 3H), 0.84 (s, 9H), 
0.03 (s, 3H), 0.02 (s, 3H). 
 
Spectral data for mixture of 73 
13C δ 154.0, 146.7, 136.7 (-), 136.5 (-), 135.1 (-), 116.9 (+), 116.3 (+), 85.1, 79.2, 
78.9,78.9, 70.8 (-), 70.2 (-), 67.2, 60.4 (-), 60.1 (-), 52.4 (-), 51.7 (-), 50.6 (-), 50.4 (-), 
40.0 (+), 39.0 (+), 33.7 (+), 32.3 (+), 28.6 (-), 28.5, 27.4 (-), 25.8 (-), 25.7 (-), 22.3 (-), 





(2R, 3R, 5R)-2-Allyl-1-(tert-butoxycarbonyl)-3-hydroxy-5-methylpyrrolidine (74) 
and (2S, 3R, 5R)-2-allyl-1-(tert-butoxycarbonyl)-3-hydroxy-5-methylpyrrolidine108 
(75) 
Tetrabutylammonium fluoride (1 M in THF, 9.5 ml) was added to a solution of 72 (1.58 
g, 4.44 mmol) in THF (20 ml) at 0 ºC.  The reaction mixture was stirred for 45.5 h., 
during which the ice bath expired.  The reaction mixture was poured into H2O (100 ml), 
extracted with EtOAc (4x100ml), dried (MgSO4), and the solvents were removed on a 
rotary evaporator at water aspirator pressure.  Purification by chromatography 
(hexanes/EtOAc, 7:3) gave 74 (795 mg, 3.29 mmol, 74%) followed by 75 (153 mg, 0.63, 
14%). 
 
Spectral data for rotameric mixture 74 
1H NMR δ 5.88-5.95 (m, 1H), 5.10 (d, J=17.4 Hz, 1H), 5.02 (d, J=10.2 Hz, 1H), 4.54 (s, 
1H), 3.89 (br s, 2H), 2.91 (br s, 1H), 2.55 (s, 1H), 2.37 (s, 1H), 2.04-2.08 (m, 1H), 1.78-
1.82 (m, 1H), 1.47 (s, 9H), 1.19 (br s, 3H);  13C δ 154.0 (+), 136.3 (-), 116.5 (+), 79.3 (+), 
70.4 (-), 70.1 (-), 59.5 (-), 50.5 (-), 39.2 (+), 38.2 (+), 33.6 (+), 32.3 (+), 28.4 (-), 21.8 (-), 
20.7 (-);  IR (neat) 3436, 1663, 1366, 1172, 1063 cm-1;  [α]25D =  -39.6 (c = 1.02, CHCl3);  
HRMS (ESI) calcd for C13H23NO3 (M+H+) 242.17569, found 242.17507. 
 
Partial spectral data for rotameric mixture 74 at (-20 ºC) 
1H NMR δ 5.92 (ddt, J=24.6, 9.6, 7.2 Hz, 1H), 5.11 (dd, J=17.4, 7.8 Hz, 1H), 5.03 (d, 
J=10.2 Hz, 1H), 4.54 (dt, J=10.2, 6.6 Hz, 1H), 3.97 (dt, J=7.2, 3.0 Hz, 0.5H), 3.82-3.91 
(m, 1.5H), 3.69 (br s, 0.5H), 3.62 (br s, 0.5H), 2.57 (pent, J=7.2, 0.5 Hz, 0.5H), 2.51 
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(pent, J=7.2, 0.5 Hz, 0.5H), 2.42-2.45 (m, 0.5H), 2.30-2.33 (m, 0.5H), 2.07 (ddt, J=15.6, 
11.4, 9.0 Hz, 1H), 1.82 (dt, J=12.6, 6.0 Hz, 1H), 1.47 (d, J=6.6 Hz, 9H), 1.46 (s, 9H), 
1.18 (dd, J=16.8, 6.0 Hz, 3H);  13C δ 154.0, 153.9, 136.3, 136.1, 116.7, 116.6, 79.4, 79.2, 
70.0, 69.6, 59.4, 59.1, 50.5, 50.1, 38.5, 37.6, 33.6, 32.2, 28.3, 21.7, 20.6 
 
Partial spectral data for rotameric mixture 74 at (+60 ºC) 
1H NMR δ 5.91 (ddt, J=24.6, 10.2, 7.2 Hz, 1H), 5.11 (dq, J=17.4, 1.8 Hz, 1H), 5.02 (d 
with further fine splitting, J=10.2 Hz, 1H), 4.51 (dt, J=16.8, 7.2 Hz, 1H), 3.93 (br s, 1H), 
3.87 (pent, J=6.6 Hz, 1H), 2.54 (pent, J=7.2 Hz, 1 Hz, 0.5H), 2.45 (br s, 1H), 2.21 (br s, 
1H), 2.04 (ddt, J=12.0, 10.8, 9.0 Hz, 1H), 1.79 (ddd, J=12.0, 6.6, 1.8 Hz, 1H), 1.47 (s, 
9H), 1.19 (d, J=6.0 Hz, 3H);  13C δ 154.1, 136.5, 129.9, 116.5, 79.3, 70.6, 59.7, 50.7, 
39.2, 33.0, 28.5, 28.4, 21.3 
 
Spectral data for rotameric mixture 75 
1H NMR δ 5.77-5.84 (m, 1H), 5.06-5.09 (m, 2H), 4.11 (s, 1H), 4.00 (br s, 1H), 3.78 (s, 
1H), 2.42 (br s, 1H), 2.06-2.09 (m, 3H), 1.74-1.79 (m, 1H), 1.47 (s, 9H), 1.27 (br s, 3H);  
13C δ 155.1 (+), 134.8 (-), 117.2 (+), 79.3 (+), 73.2 (-), 66.8 (-), 52.1 (-), 40.6 (+), 38.6 
(+), 28.5 (-), 21.9 (-);  IR (neat) 3405, 1664, 1390, 1169, 1096 cm-1;  [α]25D =  -8.1 ±0.7 (c 







Partial spectral data for rotameric mixture 75 at (-55 ºC) 
1H NMR δ 5.77-5.84 (m, 1H), 5.07-5.10 (m, 2H), 4.10 (br s, 1H), 4.00 (bs, 1H), 3.94-
4.01 (m, 2H), 3.78-3.83 (m, 1H), 2.37-39 (m, 0.5H), 2.28-2.31 (m, 0.5H), 2.07-2.16 (m, 
1.5H), 2.00 (dt, J=13.8, 9.0 Hz, 0.5H), 1.46 (s, 9H), 1.28 (dd, J=15.6, 6.0 Hz, 3H);  13C δ 
115.2, 115.0, 134.7, 117.3, 117.2, 79.4, 72.8, 71.9, 66.3, 66.2, 51.9, 51.9, 39.8, 39.6, 38.4, 
38.3, 28.2, 22.4, 21.6. 
 
Partial spectral data for rotameric mixture 75 at (+60 ºC) 
1H NMR δ 5.81 (ddt, J=16.8, 10.2, 6.9 Hz, 1H), 5.05-5.09 (m, 2H), 4.11(t, J=1.2 Hz, 
1H), 4.00 (q, J=6.6 Hz, 1H), 3.76 (br s, 1H), 2.42-2.44 (m, 1H), 2.09 (dt with further fine 
splitting, J=15.0, 7.8 Hz, 1H), 2.05 (dddd, J=13.7, 7.4, 2.7, 1.3 Hz, 1H), 1.76 (ddd, 
J=13.8, 8.4, 4.8 Hz, 1H), 1.73 (br s, 1H), 1.47 (s, 9H), 1.26 (d, J=6.6 Hz, 3H);  13C δ 
155.1, 134.9, 117.1, 79.3, 73.7, 67.0, 52.3, 40.8, 38.6, 28.6, 22.1. 
 
(S)-2-(2-Bromo-3-nitrophenoxy)butane-1,4-dimethanesulfonate114 (79) 
To a solution of 62 (581 mg, 2.09 mmol) in THF (5 ml) were added triphenylphosphine 
(827 mg, 3.15 mmol) and 47 (685 mg, 3.14 mmol).  The solution was cooled to 0 ºC and 
DIAD (0.63 ml, 3.18 mmol) was added dropwise.  The cold bath was removed and the 
mixture was stirred 2 h, concentrated, diluted with CH2Cl2 (10 ml), washed with 1 M 
NaOH (10 ml) and 1 M HCl (10 ml), and dried (MgSO4).  Purification by 
chromatography (hexanes/EtOAc, 1:9) gave 79 (936 mg, 2.02 mmol, 97%).  1H NMR δ 
7.45 (dt, J=7.8, 1.8 Hz, 1H), 7.39 (d, J=7.8 Hz, 1H), 7.28 (d, J=8.4 Hz, 1H), 4.89 (pent, 
J=5.4 Hz, 1H), 4.41-4.47 (m, 4H), 3.03 (d, J=1.8 Hz, 3H), 2.99 (d, J=1.8 Hz, 3H), 2.29 
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(q, J=5.4 Hz, 2H);  13C δ 155.2, 151.8, 129.0, 118.1, 118.0, 105.8, 74.6, 69.0, 65.3, 37.5, 
37.2, 30.8;  IR (neat) 1532, 1346, 1167, 961, 794 cm-1;  [α]25D =  -24.3 (c = 1.0, CHCl3);  
Anal. Calcd. for C12H16BrNO9S2: C, 31.18; H, 3.49. Found: C, 31.51; H, 3.66. 
 
(S)-4-(2-Bromo-3-nitrophenoxy)-3,4-dihydro-2H-pyrrole N-oxide114 (80)  
A suspension of 79 (216 mg, 0.47 mmol) and hydroxylamine hydrochloride (149 mg, 
2.14 mmol) in triethylamine (5 ml) was heated at reflux for 2.5 h.The solvents were 
removed and the resulting crude material was washed with diethyl ether (4x5 ml).  The 
ethereal extracts were concentrated, dissolved in CH2Cl2 (5 ml), and cooled to 0 ºC.  
MnO2 (61.3 mg, 0.71 mmol) was added, the cold bath was removed, and the solution was 
stirred at room temperature for 2 h.  The solution was filtered through a short pad of 
Celite and MgSO4.  The solvents were removed on a rotary evaporator at water aspirator 
pressure and purification by chromatography (hexanes/EtOAc, 1:1) gave 80 (35 mg, 
0.12 mmol, 25%).  1H NMR δ 7.43 (t, J=8.4 Hz, 1H), 7.40 (d, J=7.8 Hz, 1H), 7.11 (s, 
1H), 7.09 (d, J=7.8 Hz, 1H), 5.53 (d, J=7.8 Hz, 1H), 4.35 (pent, J=8.4 Hz, 1H), 4.01 
(ddd, J=13.8, 9.0, 4.2 Hz, 1H), 2.81 (ddt, J=14.4, 8.4, 7.2 Hz, 1H), 2.49-2.54 (m, 1H);  
13C δ 155.0 (+), 152.2 (+), 130.7 (-), 128.8 (-), 118.1 (-), 117.5 (-), 106.5 (+), 79.6 (-), 
61.4 (+), 27.4 (+);  IR (neat) 3232, 1582, 1531, 1455, 1107 cm-1. 
 
(2R, 3S)-2-Allyl-3-(2-bromo-3-nitrophenoxy)-1-methylpyrrolidine114 (82) 
To a solution of 63 (265 mg, 1.88 mmol) in THF (5 ml) were added triphenylphosphine 
(739 mg, 2.82 mmol) and 47 (614 mg, 2.82 mmol).  The solution was cooled to 0 ºC and 
DIAD (0.56 ml, 2.82 mmol) was added dropwise.  The cold bath was removed and the 
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mixture was stirred 10 h., concentrated, diluted with CH2Cl2 (25 ml), washed with 1 M 
NaOH (25 ml) and 1 M HCl (25 ml), and dried (MgSO4).  Purification by 
chromatography (MeOH) gave 82 (187 mg, 0.55 mmol, 29%). 
 
(2R, 3S)-2-Allyl-3-(2-iodo-3-nitrophenoxy)-1-methylpyrrolidine114 (83) 
To a solution of 63 (92.7 mg, 0.66 mmol) in THF (2 ml) were added triphenylphosphine 
(284 mg, 1.08 mmol) and 48 (282 mg, 1.06 mmol).  The solution was cooled to 0 ºC and 
DIAD (0.21 ml, 1.06 mmol) was added dropwise.  The cold bath was removed and the 
mixture was stirred 2 h, concentrated, diluted with CH2Cl2 (10 ml), washed with 1 M 
NaOH (10 ml) and 1 M HCl (10 ml), and dried (MgSO4).  Purification by 
chromatography (hexanes/EtOAc, 3:7 then 1:9) gave 83 (129 mg, 0.33 mmol, 50%).  1H 
NMR δ 7.38 (t, J=8.4 Hz, 1H), 7.27 (dd, J=7.8 Hz, 1.2, 1H), 6.88 (dd, J=8.4 Hz, 1.2, 1H), 
5.87 (ddt, J=17.0, 10.0, 7.0 Hz, 1H), 5.11 (dq, J=16.8 Hz, 1.2, 1H), 5.05 (d with other 
fine splitting, J=10.8 Hz, 1H), 4.56 (ddd, J=6.6, 4.2, 1.8 Hz, 1H), 3.09 (t, J=8.4 Hz, 1H), 
2.67-2.70 (m, 1H), 2.58-2.62 (m, 1H), 2.46-2.51 (m, 1H), 2.45 (s, 3H), 2.28 (dt, J=14.4, 
7.2 Hz, 1H), 2.18 (ddt, J=13.8, 11.4, 7.2 Hz, 1H), 1.80 (dd, J=13.8, 6.6 Hz, 1H);  13C δ 
158.0 (+), 155.8 (+), 134.5 (-), 129.8 (-), 117.3 (+), 116.7 (-), 115.5 (-), 83.7 (-), 81.2 (+), 
70.8 (-), 55.0 (+), 40.7 (-), 36.2 (+), 30.2 (+);  HRMS (ESI) calcd for C14H17IN2O3 








methylpyrrolidine114 (84)  
To a solution of 74 (295 mg, 1.22 mmol) in THF (5 ml) were added triphenylphosphine 
(482 mg, 1.84 mmol) and 47 (400 mg, 1.83 mmol).  The solution was cooled to 0 ºC and 
DIAD (0.37 ml, 1.87 mmol) was added dropwise.  The cold bath was removed and the 
mixture was stirred 3 h, concentrated, diluted with CH2Cl2 (10 ml), washed with 1 M 
NaOH (10 ml) and 1 M HCl (10 ml), and dried (MgSO4).  Purification by 
chromatography (hexanes/EtOAc, 7:3 then 1:1) gave 84 (224 mg, 0.51 mmol, 41%) 
followed by starting material 74 (134 mg). 
 
Spectral data for rotameric mixture 84 
1H NMR δ 7.38 (t, J=7.8 Hz, 0.5H), 7.35 (t, J=7.2 Hz, 0.5H), 7.30 (d, J=9.0 Hz, 0.5H), 
7.29 (d, J=8.4 Hz, 1H), 5.80-5.90 (m, 1H), 5.19 (d, J=16.8 Hz, 1H), 5.18 (d, J=10.8 Hz, 
1H), 4.70 (s, 0.5H), 4.69 (s, 0.5H), 3.96-4.14 (m, 2H), 2.77 (d, J=13.2 Hz, 0.5H), 2.62 (d, 
J=9.6 Hz, 0.5H), 2.44-2.52 (m, 1H), 2.14-2.20 (m, 1H), 1.96-2.04 (m, 1H), 1.48 (s, 9H);  
13C δ 155.3, 155.2, 153.8, 153.3, 152.2, 152.2, 134.3 (-), 134.0 (-), 128.4 (-), 128.3 (-), 
118.7 (+), 118.6 (+), 116.6 (-), 116.5 (-), 116.1 (-), 116.0 (-), 105.5, 105.3, 82.4 (-), 81.1 
(-), 79.6, 79.6, 62.9 (-), 62.7 (-), 60.3, 53.2 (-), 53.1 (-), 37.4 (+), 36.4 (+), 36.1 (+), 35.5 
(+), 28.4 (-), 21.7 (-), 20.5 (-);  IR (neat) 2976, 1682, 1534, 1387, 1269 cm-1;  [α]25D =  






methylpyrrolidine114 (85)  
To a solution of 74 (240 mg, 1.0 mmol) in THF (5 ml) were added triphenylphosphine 
(395 mg, 1.51 mmol) and 48 (398 mg, 1.50 mmol).  The solution was cooled to 0 ºC and 
DIAD (0.30 ml, 1.51 mmol) was added dropwise.  The cold bath was removed and the 
mixture was stirred 4 h, concentrated, diluted with CH2Cl2 (10 ml), washed with 1 M 
NaOH (10 ml) and 1 M HCl (10 ml), and dried (MgSO4).  Purification by 
chromatography (hexanes/EtOAc, 1:1 then EtOAc) gave 85 (315 mg, 0.65 mmol, 65%). 
 
Spectral data for rotameric mixture 85 
1H NMR δ 7.39 (t, J=7.8 Hz, 0.5H), 7.37 (t, J=7.8 Hz, 0.5H), 7.27 (d, J=7.2 Hz, 0.5H), 
7.26 (d, J=7.8 Hz, 0.5H), 6.94 (d, J=8.4 Hz, 1H), 5.81-5.90 (m, 1H), 5.18 (d, J=16.8 Hz, 
1H), 5.18 (d, J=10.2 Hz, 1H), 4.66 (s, 0.5H), 4.66 (s, 0.5H), 4.00-4.19 (m, 2H), 2.77 (d, 
J=12.0 Hz, 0.5H), 2.61 (d, J=10.8 Hz, 0.5H), 2.46-2.54 (m, 1H), 2.15-2.23 (m, 1H), 1.98-
2.04 (m, 1H), 1.51-1.54 (m, 3H), 1.48 (s, 9H);  13C δ 159.9, 158.0, 157.9, 156.2, 156.1, 
153.9, 153.4, 134.3 (-), 134.1 (-), 129.8 (-), 129.7 (-), 118.7 (+), 118.6 (+), 116.8 (-), 
116.8 (-), 115.0 (-), 114.9 (-), 82.8 (-), 81.5 (-), 81.0, 80.8, 79.7, 79.7, 74.3, 63.0 (-), 62.9 
(-), 60.3, 53.3 (-), 53.2 (-), 37.5 (+), 36.5 (+), 36.1 (+), 35.6 (+), 28.5 (-), 22.1 (-), 21.9 (-), 
21.7 (-), 21.6 (-), 21.0, 20.9, 14.2;  IR (neat) 1680, 1532, 1364, 1110, 1020 cm-1;  [α]25D =  






Tricyclic compound 87117 
A solution of 85 (95.9 mg, 0.20 mmol), Pd(OAc)2 (4.6 mg, 0.02 mmol), PPh3 (4.9 mg, 
0.02 mmol), and Ag2CO3 (112 mg, 0.41 mmol) in DMF (5 ml) was stirred at 120 ºC for 
64.5 h.  The solvents were removed on a rotary evaporator at water aspirator pressure, 
dissolved in CH2Cl2 (20 ml), filtered (Celite), concentrated, and the residue was purified 
by chromatography (hexanes/EtOAc, 7:3 then 1:1) to give 87 (26.7 mg, 0.07 mmol, 
35%). 
 
Alternate procedure: A solution of Pd(OAc)2 (7.4 mg, 0.03 mmol) and tri(o-
tolyl)phosphine (39.4 mg, 0.13 mmol) in triethylamine (3 ml) was stirred (5 min.) at 
ambient temperature.  Compound 84 (200 mg, 0.45 mmol) in triethylamine (4 ml) was 
added and the resulting mixture was heated at 120 OC (31 h).  The solvents were removed 
on a rotary evaporator at water aspirator pressure and the residue was purified by 
chromatography (hexanes/EtOAc, 9:1) to give 87 (46.8 mg, 0.13 mmol, 29%). 
 
Alternate procedure: A solution of 84 (114 mg, 0.26 mmol), Pd(OAc)2 (6.9 mg, 0.03 
mmol), PPh3 (4.7 mg, 0.02 mmol), and Ag2CO3 (146 mg, 0.53 mmol) in DMF (5 ml) was 
stirred at 120 ºC for 67 h.  The solvents were removed on a rotary evaporator at water 
aspirator pressure, dissolved in CH2Cl2 (20 ml), filtered (Celite), concentrated, and the 






Spectral data for rotameric mixture 87 
1H NMR δ 7.63 (dd, J=7.2, 2.4 Hz, 1H), 7.24-7.28 (m, 2H), 6.08 (br s, 1H), 5.83 (br s, 
0.5H), 5.73 (br s, 0.5H), 4.90 (br s, 1H), 3.80 (ddt, J=16.8, 10.2, 7.2 Hz, 3H), 3.29 (dd, 
J=12.6, 7.2 Hz, 1H), 2.57 (br s, 1H), 1.93 (dt, J=12.6, 10.8 Hz, 1H), 1.48 (s, 9H), 1.45 (s, 
3H);  13C δ 158.8, 153.9, 149.9, 136.2, 134.3, 133.2, 128.4, 128.2, 127.7 (-), 127.3 (-), 
126.8, 125.9, 120.6, 120.5, 87.3, 86.8 (-), 80.0, 61.8 (-), 56.4, 52.2 (-), 51.6 (-), 40.3 (+), 
37.4 (+), 28.4 (-), 26.4 (+), 21.8, 20.1;  IR (neat) 1691, 1528, 1154, 1031, 712 cm-1;  
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Figure 63: DEPT of (3R, 5R)-2-Allyl-3-[(tert-butyldimethylsilyl)oxy]-methylpyrrolidine 72 
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Figure 69: DEPT of (2R,3R)-2-Allyl-1-methylpyrrolidin-3-ol 63 
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Figure 93: DEPT of tricyclic compound 87 
